Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Progenitor cells from which all blood cells derive.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transplantation of an individual's own tissue from one site to another site.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
Immunological rejection of leukemia cells following bone marrow transplantation.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The transference of a part of or an entire liver from one human or animal to another.
The return of a sign, symptom, or disease after a remission.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Disorders of the blood and blood forming tissues.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
Providers of tissues for transplant to non-related individuals.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
A particular zone of tissue composed of a specialized microenvironment where stem cells are retained in a undifferentiated, self-renewable state.
Elements of limited time intervals, contributing to particular results or situations.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Cells with high proliferative and self renewal capacities derived from adults.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
The transference of a kidney from one human or animal to another.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
Tissues, cells, or organs transplanted between genetically different individuals of the same species.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Disease having a short and relatively severe course.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
Cells that can give rise to cells of the three different GERM LAYERS.
Specialized stem cells that are committed to give rise to cells that have a particular function; examples are MYOBLASTS; MYELOID PROGENITOR CELLS; and skin stem cells. (Stem Cells: A Primer [Internet]. Bethesda (MD): National Institutes of Health (US); 2000 May [cited 2002 Apr 5]. Available from: http://www.nih.gov/news/stemcell/primer.htm)
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Transference of an organ between individuals of the same species or between individuals of different species.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
The transference of a heart from one human or animal to another.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Cells derived from a FETUS that retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The transference of either one or both of the lungs from one human or animal to another.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Self-renewing cells that generate the main phenotypes of the nervous system in both the embryo and adult. Neural stem cells are precursors to both NEURONS and NEUROGLIA.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Formation of LYMPHOCYTES and PLASMA CELLS from the lymphoid stem cells which develop from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW. These lymphoid stem cells differentiate into T-LYMPHOCYTES; B-LYMPHOCYTES; PLASMA CELLS; or NK-cells (KILLER CELLS, NATURAL) depending on the organ or tissues (LYMPHOID TISSUE) to which they migrate.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
Methods for maintaining or growing CELLS in vitro.
The blood-making organs and tissues, principally the bone marrow and lymph nodes.
A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked.
Cells from adult organisms that have been reprogrammed into a pluripotential state similar to that of EMBRYONIC STEM CELLS.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
One of a pair of excretory organs (mesonephroi) which grows caudally to the first pair (PRONEPHROI) during development. Mesonephroi are the permanent kidneys in adult amphibians and fish. In higher vertebrates, proneprhoi and most of mesonephroi degenerate with the appearance of metanephroi. The remaining ducts become WOLFFIAN DUCTS.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
The physiological renewal, repair, or replacement of tissue.
The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A general term for various neoplastic diseases of the lymphoid tissue.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
Transplantation between animals of different species.
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Infections with fungi of the genus ASPERGILLUS.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
A genus of the family RETROVIRIDAE consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3' env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species.
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
The number of CELLS of a specific kind, usually measured per unit volume or area of sample.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
Infection with ROSEOLOVIRUS, the most common in humans being EXANTHEMA SUBITUM, a benign disease of infants and young children.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
An organism whose body contains cell populations of different genotypes as a result of the TRANSPLANTATION of donor cells after sufficient ionizing radiation to destroy the mature recipient's cells which would otherwise reject the donor cells.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
The number of LYMPHOCYTES per unit volume of BLOOD.
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive.
Transference of fetal tissue between individuals of the same species or between individuals of different species.
Antibodies produced by a single clone of cells.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Stem cells derived from HEMATOPOIETIC STEM CELLS. Derived from these myeloid progenitor cells are the MEGAKARYOCYTES; ERYTHROID CELLS; MYELOID CELLS; and some DENDRITIC CELLS.
A decrease in the number of NEUTROPHILS found in the blood.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).
Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
The transference of a pancreas from one human or animal to another.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A family of receptors found on NK CELLS that have specificity for a variety of HLA ANTIGENS. KIR receptors contain up to three different extracellular immunoglobulin-like domains referred to as D0, D1, and D2 and play an important role in blocking NK cell activation against cells expressing the appropriate HLA antigens thus preventing cell lysis. Although they are often referred to as being inhibitory receptors, a subset of KIR receptors may also play an activating role in NK cells.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.

Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. (1/7058)

BACKGROUND: Since 1968 it has been known that bone marrow transplantation can ameliorate severe combined immunodeficiency, but data on the long-term efficacy of this treatment are limited. We prospectively studied immunologic function in 89 consecutive infants with severe combined immunodeficiency who received hematopoietic stem-cell transplants at Duke University Medical Center between May 1982 and September 1998. METHODS: Serum immunoglobulin levels and lymphocyte phenotypes and function were assessed and genetic analyses performed according to standard methods. Bone marrow was depleted of T cells by agglutination with soybean lectin and by sheep-erythrocyte rosetting before transplantation. RESULTS: Seventy-seven of the infants received T-cell-depleted, HLA-haploidentical parental marrow, and 12 received HLA-identical marrow from a related donor; 3 of the recipients of haploidentical marrow also received placental-blood transplants from unrelated donors. Except for two patients who received placental blood, none of the recipients received chemotherapy before transplantation or prophylaxis against graft-versus-host disease. Of the 89 infants, 72 (81 percent) were still alive 3 months to 16.5 years after transplantation, including all of the 12 who received HLA-identical marrow, 60 of the 77 (78 percent) who were given haploidentical marrow, and 2 of the 3 (67 percent) who received both haploidentical marrow and placental blood. T-cell function became normal within two weeks after transplantation in the patients who received unfractionated HLA-identical marrow but usually not until three to four months after transplantation in those who received T-cell-depleted marrow. At the time of the most recent evaluation, all but 4 of the 72 survivors had normal T-cell function, and all the T cells in their blood were of donor origin. B-cell function remained abnormal in many of the recipients of haploidentical marrow. In 26 children (5 recipients of HLA-identical marrow and 21 recipients of haploidentical marrow) between 2 percent and 100 percent of B cells were of donor origin. Forty-five of the 72 children were receiving intravenous immune globulin. CONCLUSIONS: Transplantation of marrow from a related donor is a life-saving and life-sustaining treatment for patients with any type of severe combined immunodeficiency, even when there is no HLA-identical donor.  (+info)

Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. (2/7058)

Intensive chemotherapy given in early chronic phase of chronic myelogenous leukemia (CML) has resulted in high numbers of circulating Philadelphia (Ph) chromosome-negative hematopoietic progenitor cells (HPC). We have autografted 30 consecutive patients with CML in chronic phase with HPC collected in this way to facilitate restoration of Ph-negative hematopoiesis in bone marrow after high-dose therapy. Hematopoietic recovery to greater than 0.5 x10(9)/L neutrophils and to greater than 25 x 10(9)/L platelets occurred in all patients, a median of 13 (range, 9 to 32) days and 16 (range, 6 to 106) days postautograft, respectively. Regenerating marrow cells were Ph-negative in 16 (53%) patients and greater than 66% Ph-negative in 10 (33%) patients. Twenty-eight patients are alive 6 to 76 months (median, 24 months) after autografting. Three patients have developed blast crisis from which 2 have died. Eight patients are in complete cytogenetic remission at a median of 20 (range, 6 to 44) months with a median ratio BCR-ABL/ABL of 0.002 (range, <0.001 to 0.01). Eight patients are in major cytogenetic remission at a median of 22 (range, 6 to 48) months. No patient died as a consequence of the treatment. All patients had some degree of stomatitis that was severe in 15 (50%) patients. Gastrointestinal and hepatic toxicities were observed in about one fourth of patients. Thus, autografting with Ph-negative mobilized HPC can result in prolonged restoration of Ph-negative hematopoiesis for some patients with CML; moreover, most autograft recipients report normal or near normal activity levels, suggesting that this procedure need not to be associated either with prolonged convalescence or with chronic debility.  (+info)

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. (3/7058)

Hematopoietic reconstitution of ablated recipients requires that intravenously (IV) transplanted stem and progenitor cells "home" to organs that support their proliferation and differentiation. To examine the possible relationship between homing properties and subsequent engraftment potential, murine bone marrow (BM) cells were labeled with fluorescent PKH26 dye and injected into lethally irradiated hosts. PKH26(+) cells homing to marrow or spleen were then isolated by fluorescence-activated cell sorting and assayed for in vitro colony-forming cells (CFCs). Progenitors accumulated rapidly in the spleen, but declined to only 6% of input numbers after 24 hours. Although egress from this organ was accompanied by a simultaneous accumulation of CFCs in the BM (plateauing at 6% to 8% of input after 3 hours), spleen cells remained enriched in donor CFCs compared with marrow during this time. To determine whether this differential homing of clonogenic cells to the marrow and spleen influenced their contribution to short-term or long-term hematopoiesis in vivo, PKH26(+) cells were sorted from each organ 3 hours after transplantation and injected into lethally irradiated Ly-5 congenic mice. Cells that had homed initially to the spleen regenerated circulating leukocytes (20% of normal counts) approximately 2 weeks faster than cells that had homed to the marrow, or PKH26-labeled cells that had not been selected by a prior homing step. Both primary (17 weeks) and secondary (10 weeks) recipients of "spleen-homed" cells also contained approximately 50% higher numbers of CFCs per femur than recipients of "BM-homed" cells. To examine whether progenitor homing was altered upon ex vivo expansion, highly enriched Sca-1(+)c-kit+Lin- cells were cultured for 9 days in serum-free medium containing interleukin (IL)-6, IL-11, granulocyte colony-stimulating factor, stem cell factor, flk-2/flt3 ligand, and thrombopoietin. Expanded cells were then stained with PKH26 and assayed as above. Strikingly, CFCs generated in vitro exhibited a 10-fold reduction in homing capacity compared with fresh progenitors. These studies demonstrate that clonogenic cells with differential homing properties contribute variably to early and late hematopoiesis in vivo. The dramatic decline in the homing capacity of progenitors generated in vitro underscores critical qualitative changes that may compromise their biologic function and potential clinical utility, despite their efficient numerical expansion.  (+info)

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. (4/7058)

We have evaluated the immunophenotype, functional activity and clonogenic potential of CD34+ cells from peripheral blood (PB) of normal donors before and after 4 and 6 days of G-CSF administration. The percentage and absolute number of CD34+ cells significantly increased at days 4 and 6 of G-CSF administration, compared to the steady-state level (P < 0.0001). Two-colour fluorescence analysis showed, at days 4 and 6, a lower proportion of CD34+/c-kit+ compared to the steady-state level (P < 0.0001), but a similar expression of CD13, CD33, CD38, HLA-DR and Thy-1 antigens on CD34+ cells. The expression of adhesion molecules on CD34+ cells revealed a significant reduction of CD11a (P = 0.009), CD18, CD49d and CD62L (P < 0.0001) at days 4 and 6, compared to the baseline level. Three-colour staining showed a reduction of the more immature compartment (34+/DR-/13-) and an increase of the more differentiated compartment (34+/DR+/13+). Downregulation of VLA-4 during mobilisation was seen almost exclusively on more committed cells (34+/13+); downregulation of CD62L, on the contrary, was observed on both early progenitors (34+/13-) and more committed cells (34+/13+). The expression of 34+/VLA-4+ decreased on both c-kit+ and c-kit- cells, while the expression of 34+/62L+ decreased on the c-kit+ cells only. In vivo administration of G-CSF reduced the adherence capacity of CD34+ cells to normal BM stroma; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34+ cell adherence to preformed stroma. Pre-incubation with the blocking beta2 integrin monoclonal antibody caused a reduction of CD34+ cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34+ cells correlates with a poor adhesion to BM stroma; CD34+ cells incubated in vitro with SCF showed, conversely, a higher expression of CD49d and a greater adherence capacity on normal preformed stroma.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (5/7058)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. (6/7058)

To determine the effect of G-CSF administration on both the total number of CD34+ cells and the primitive CD34+ subsets in bone marrow (BM), we have analyzed BM samples serially obtained from 10 normal donors in steady-state and during G-CSF treatment. Filgrastim was administered subcutaneously at a dosage of 10 microg/kg/day (n = 7) or 10 microg/kg/12 h (n = 3) for 4 consecutive days. Peripheral blood sampling and BM aspirates were performed on day 1 (just before G-CSF administration), day 3 (after 2 days of G-CSF), and day 5 (after 4 days of G-CSF). During G-CSF administration, a significant increase in the total number of BM nucleated cells was observed. The percentage (range) of CD34+ cells decreased in BM from a median of 0.88 (0.47-1.44) on day 1 to 0.57 (0.32-1.87), and to 0.42 (0.16-0.87) on days 3 and 5, respectively. We observed a slight increase in the total number of BM CD34+ cells on day 3 (0.66 x 10(9)/l (0.13-0.77)), and a decrease on day 5 (0.23 x 10(9)/l (0.06-1.23)) as compared with steady-state (0.40 x 10(9)/l (0.06-1.68)). The proportion of primitive BM hematopoietic progenitor cells (CD34+CD38-, CD34+HLA-DR-, CD34+CD117-) decreased during G-CSF administration. In parallel, a significant increase in the total number of CD34+ cells in peripheral blood was observed, achieving the maximum value on day 5. These results suggest that in normal subjects the administration of G-CSF for 5 days may reduce the number of progenitor cells in BM, particularly the most primitive ones.  (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (7/7058)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. (8/7058)

In these studies, we compared the phenotype, function, and expression of type 1, type 2, and monocyte-associated cytokine mRNA transcripts in autologous bone marrow (BM) and growth factor-mobilized peripheral blood stem cell (PSC) products. These studies demonstrate that lymphocytes and monocytes in stem cell products are abnormally activated, expressing significantly higher levels of interleukin (IL)-2, 4 and 10, interferon gamma (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha), but not IL-8, as compared to normal peripheral blood mononuclear cells (PBMC). In addition, the levels of IL-2, IL-10 and TNF-alpha are significantly higher in mobilized PSC as compared to BM products. The high cytokine levels are unexpected as T cell function in stem cell products is depressed. PSC products have high levels of T cell inhibitory activity, which directly correlates with IL-10 expression, both of which are mechanisms that might be involved in the immune dysfunction within stem cell products used for autologous stem cell transplantation. These data demonstrate that: (1) immune cells in autologous BM and PSC products are activated with the expression of high levels of type 1 and type 2 cytokines as well as monokines; (2) PSC products contain a high frequency of monocytes which mediate T cell inhibitory activity; and (3) despite the high levels of cytokine expression, T cell function in stem cell products is depressed. The significance of these immune abnormalities within stem cell products for myeloid and lymphoid recovery following autologous stem cell transplantation remains to be determined.  (+info)

OBJECTIVE: To explore the outcome of human leukocyte antigen (HLA)-mismatched/haploidentical hematopoietic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia (AL) patients and its related risk factors.. METHODS: 96 refractory/relapsed AL patients who received HLA-mismatched/haploidentical HSCT following conditioning regimen comprised of modified busulfan/cyclophosphamide (BU/CY) plus thymoglobulin (ATG) from Jan 2003 to Jun 2011 were analyzed retrospectively.. RESULTS: Of the 96 patients, 61 suffered from acute myeloid leukemia (AML), and 35 acute lymphoid leukemia (ALL), all of them in non-remission (NR) or relapse before transplantation. With a median follow-up of 373 (34 - 3157) d, 33 cases (34%) survived, 31 survived without leukemia, and 35 relapsed. The estimated 3-year overall survival (OS) and disease-free survival (DFS) rate was 30.2% and 29.0%, respectively. The 3-year OS rate was significantly higher for AML patients (39.2%) than for ALL patients (15.4%) (P = ...
Геморрагический энтерит, ассоциированный с парвовирусом В19 после трансплантации гемопоэтических стволовых клеток: клинический случай и данные литературыHaemorrhagic enteritis associated with parvovirus B19 following hematopoietic stem cell transplantation: a case report and literature data
A nosocomial pneumonia caused by Legionella pneumophilaserogroup 2oc-14oc curred in a 7-year-old patient following allogeneic hematopoietic stem cell transplantation for thalassemia major. The patient was diagnosed as nosocomial Legionella pneumonia by a polymerase chain reaction (PCR) from bronchoalveolar lavage and a culture of L. pneumophilaserogroup 2-14 from patients room faucet water. Legionella was eradicated from our hospitals water distribution system by superheating and chemical eradication methods (hyper-chlorination and hydrogen peroxide). We did not detect any case after this event. Early recognition of contamination of hospital water system with Leigonella proves the importance of prevention new cases. ...
A 60-year-old man presented with impaired consciousness and psychomotor agitation after a second allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor for acute myeloid leukaemia. Clinical, biological and radiological evidence suggested a diagnosis of central nervous system graft-versus-host disease (CNS-GvHD). After intrathecal infusion of methylprednisolone, the clinical symptoms as well as the radiological abnormalities disappeared. The present report illustrates the difficulties in the diagnosis and the management of CNS-GvHD, a very rare and still challenging neurological complication that can occur after allogeneic HSCT. ...
Purpose of reviewCytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is no
TY - JOUR. T1 - Respiratory virus infections in pediatric hematopoietic stem cell transplantation. AU - Luján-Zilbermann, Jorge. AU - Benaim, Ely. AU - Tong, Xin. AU - Srivastava, Deo K.. AU - Patrick, Christian C.. AU - Devincenzo, John. PY - 2001/10/1. Y1 - 2001/10/1. N2 - Respiratory virus infections (RVI) have become an increasingly appreciated problem in the hematopoietic stem cell transplant (HSCT) population. A retrospective analysis of 274 patients undergoing 281 HSCT at St. Jude Childrens Research Hospital from January 1994 through December 1997 was performed. Medical and clinical laboratory records were reviewed beginning at the onset of conditioning through the year following each HSCT, and the analysis was done for the first RVI only. Thirty-two (11%) of 281 HSCT cases developed a RVI during the first year post-HSCT. The most frequent cause of RVI was human parainfluenza virus type 3. Univariate analysis was performed to determine the association between risk factors and the ...
TY - JOUR. T1 - Rapid immune reconstitution following autologous hematopoietic stem cell transplantation in children. T2 - A single institution experience. AU - Hoepfner, S.. AU - Haut, Paul. AU - OGorman, M.. AU - Kletzel, M.. PY - 2003/2. Y1 - 2003/2. N2 - In this retrospective study, we review the immune reconstitution of children undergoing autologous hematopoietic stem cell transplantation. A total of 125 patients underwent autologous transplantation between 1992 and 2000. The report includes data on 58 patients. Data were not available on the remaining patients who either died before testing or data were not obtained. The parameters evaluated include: (a) immunophenotype by flow cytometry to quantify lymphocyte subpopulations (b) mitogen stimulation assays, and (c) quantitative immunoglobulins. The analysis reveals that CD3+ cells did not reach the normal range during the first year post-transplant. The median percentage of CD4 + cells was below normal up to 6 months post-transplant, ...
Background. Haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) is associated with an increased risk of graft failure and severe graft-versus-host disease (GVHD). Marrow mesenchymal stromal cells (MSCs) have been shown to support in vivo normal hematopoiesis and to display potent immunosuppressive effects. We launched a multi-center clinical study to examine the safety and feasibility of co-transplantation of MSCs (from third party donors) and haploidentical HSCs into 35 children with severe aplastic anemia (SAA). Methods. A total of 35 children with SAA were enrolled in this multi-center study between January 2014 and December 2016. All patients met the criteria of HLA-mismatched with ⩾5/10 HLA-matched loci. The conditioning regimen for haploidentical hematopoietic stem cell transplantation consisted of busulfan (Bu), cyclophosphamide and ATG. BM and peripheral blood CD34+ cells were infused intravenously ⩾5×108 cells/kg and ⩾2×106 cells/kg of recipient weight on day 01 ...
According to a recently published report by Brisk Insights, the Global Hematopoietic Stem Cells Transplantation Market is expected to grow at the CAGR of 10.4 % during 2017-2025. The global hematopoietic stem cells transplantation market is segmented on the basis of application, transplant type, and geography. The report on global hematopoietic stem cells transplantation market (by application, transplant type, and geography) provides a detailed overview and predictive analysis of the market.. Full report available on Hematopoietic Stem Cells Transplantation Market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/hematopoietic-stem-cells-transplantation-market. Market Insights. Increasing prevalence of cancer and anemia in both developed and developing nations are the key growth factors in the hematopoietic stem cells transplantation market. In base year 2016, lymphoproliferative disorders and leukemia accounted for more than 50% of the ...
PubMedID: 23505556 | Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation. | PloS one | 1/1/2013
TY - JOUR. T1 - Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. AU - Muller, William J.. AU - Levin, Myron J.. AU - Shin, Young Kyoo. AU - Robinson, Christine. AU - Quinones, Ralph. AU - Malcolm, Janet. AU - Hild, Elaine. AU - Gao, Dexiang. AU - Giller, Roger. PY - 2005/12/15. Y1 - 2005/12/15. N2 - Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT patients, 18 of whom had severe manifestations of infection. Cidofovir treatment led to clinical improvement in 8 of 10 patients with severe infection and to virologic clearance in 9 patients. In vitro susceptibility to cidofovir was demonstrated in 12 clinical adenovirus isolates. Cidofovir is a promising treatment option for this population.. AB - Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT ...
TY - JOUR. T1 - Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. AU - Busca, Alessandro. AU - Locatelli, F.. AU - Barbui, A.. AU - Ghisetti, V.. AU - Cirillo, D.. AU - Serra, R.. AU - Audisio, E.. AU - Falda, M.. PY - 2003/9. Y1 - 2003/9. N2 - Nonmyeloablative hematopoietic stem cell transplantation (NST) has been explored in hematological malignancies and solid tumors in an attempt to minimize treatment-related toxicity. Whether this approach is associated with reduced risk of infectious complications is unclear. The aim of the current study was to evaluate the infectious complications in a series of 32 consecutive adult patients who received NSTat our institution. Peripheral blood stem cell grafts (n = 30) or marrow grafts (n = 2) were infused from human leukocyte antibody (HLA)·matched sibling (n = 30), partially matched related (n = 1), or unrelated (n = 1) donors. Neutropenia developed in two-thirds of patients and lasted 16 days. ...
Introduction. Cyclosporin (CSA) is commonly used as graft vs host disease (GvHD) prophylaxis in allogeneic haematopoietic stem cell transplant (alloHSCT) recipients. The usual IV dose is 3mg/kg and the recommended oral dose at switching is 3mg/kg BD in the pre-posaconazole era (Inoue et al. 2014). Posaconazole is now commonly used as antifungal prophylaxis in this context; it increases CSA levels through inhibition of the cytochrome involved in CSA metabolism (Sánchez-Ortega et al. 2012). We evaluated CSA-related toxicity after switch from IV to oral CSA in alloHSCT recipients receiving posaconazole with the aim of defining the optimal weight based oral dose.. Methods. A retrospective audit was performed of adult alloHSCT patients between October 2015 and October 2017 who received IV and then oral CSA together with posaconazole prophylaxis. Posaconazole was commenced during conditioning and continued at 300mg IV or oral daily according to gastrointestinal tolerance; patients with levels below ...
TY - JOUR. T1 - Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. AU - Lupo-Stanghellini, Maria Teresa. AU - Provasi, Elena. AU - Bondanza, Attilio. AU - Ciceri, Fabio. AU - Bordignon, Claudio. AU - Bonini, Chiara. PY - 2010/3/1. Y1 - 2010/3/1. N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most ...
Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion CD3±CD19 cells may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation.. Purpose: This phase I/II trial is to evaluate the safety and efficacy of fludarabine, cyclophosphamide and antithymocyte globulin with CD3±CD19 depleted graft from haploidentical donors in treating patients with aplastic anemia. ...
EV Morozova, YuYu Vlasova, MV Barabanshchikova, NN Mamaev, IM Barkhatov, AL Alyanskii, EI Darskaya, MV Vladovskaya, SN Bondarenko, IS Moiseev, BV Afanasyev RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022 For correspondence: Elena Vladislavovna Morozova, MD, PhD, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022; e-mail: [email protected] For citation: Morozova EV, Vlasova YuYu, Barabanshchikova MV, et al. Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors. Clinical oncohematology. 2020;13(2):193-8 (In Russ). DOI: 10.21320/2500-2139-2020-13-2-193-198 ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a radical method of chronic myeloid leukemia (CML) treatment. In the 1990s CML became the most frequent
TY - JOUR. T1 - Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHD-related dry eye. AU - Wang, Y.. AU - Ogawa, Y.. AU - Dogru, M.. AU - Tatematsu, Y.. AU - Uchino, M.. AU - Kamoi, M.. AU - Okada, N.. AU - Okamoto, S.. AU - Tsubota, K.. PY - 2010/6/1. Y1 - 2010/6/1. N2 - We evaluated ocular surface alterations in allogeneic hematopoietic stem cell transplantation (HSCT) recipients with or without chronic GVHD-related dry eye in a prospective study. Fifty eyes of 25 post-HSCT patients and 28 eyes of 14 age-matched healthy controls were included. Meibomian gland (MG) obstruction, tear evaporation rate, corneal sensitivity (CS), Schirmer test-I, tear break-up time (BUT) and ocular surface vital staining were examined. Conjunctival impression and brush cytology specimens were collected to evaluate the goblet cell density (GCD) and the inflammatory cell numbers. Obvious MG obstruction, decreased CS and ...
TY - JOUR. T1 - Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation. AU - Saburi, Masuho. AU - Kohashi, Sumiko. AU - Kato, Jun. AU - Koda, Yuya. AU - Sakurai, Masatoshi. AU - Toyama, Takaaki. AU - Kikuchi, Taku. AU - Karigane, Daiki. AU - Yuda, Sayako. AU - Yamane, Yusuke. AU - Hashida, Risa. AU - Abe, Ryohei. AU - Nakazato, Tomonori. AU - Hirahashi, Junichi. AU - Ogata, Masao. AU - Okamoto, Shinichiro. AU - Mori, Takehiko. PY - 2017/5/17. Y1 - 2017/5/17. N2 - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT ...
Historically, unmanipulated T-cell-replete haploSCT grafts with conventional graft-versus-host-disease (GVHD) prophylaxis used in the late 1970s were associated with intense bidirectional alloreactivity and unacceptably high morbidity and mortality rates due to hyperacute GVHD and graft rejection (4,5,6). This led in the 1980s to the development of complete ex vivo depletion of T cells using CD34-selected grafts. Complete T-cell depletion has been associated with a lower incidence of acute GVHD (aGVHD); however, this caused delayed immune recovery and was associated with a high nonrelapse mortality (NRM) from infections and higher disease relapse rates given the decreased graft-versus-leukemia effect, as well as a higher rate of graft rejection (7,8,9). While graft rejection was partially overcome with megadoses of CD34 cells (typically >107 CD34+ cells/kg) and a myeloablative conditioning regimen (including total-body irradiation [TBI], cyclophosphamide, thiotepa) with severe T-cell depletion ...
Highly diverse bacterial populations inhabit the gastrointestinal tract and modulate host inflammation and promote immune tolerance. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the gastrointestinal mucosa is damaged, and colonizing bacteria are impacted, leading to an impaired intestinal microbiota with reduced diversity. We examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allo-HSCT at the time of stem cell engraftment. Bacterial 16S rRNA gene sequences were characterized, and microbial diversity was estimated using the inverse Simpson index. Subjects were classified into high, intermediate, and low diversity groups, and assessed for differences in outcomes. Mortality outcomes were significantly worse in patients with lower intestinal diversity; overall survival at three years was 36%, 60%, and 67% for low, intermediate, and high diversity groups, respectively ...
BACKGROUND & OBJECTIVE: Patients with refractory or relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation had a poor prognosis with high death rate due to relapse or transplant-related mortality (TRM). The purpose of this paper was to clarify the role of inducing acute graft-versus-host disease (aGVHD) during transplantation in preventing relapse.. METHODS: Thirty adult patients with refractory or relapsed leukemia were acute lymphoblastic leukemia (n=16), acute myelogenous leukemia (n=10), and acute mixed leukemia (n=4). They were in first complete remission (n=4), second complete remission (n=9), partly remission (n=12), and non-response (n=5) at the time of transplantation. Patients underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from HLA-identical siblings (n=21), mismatched siblings donors (n=3), and allogeneic bone marrow transplantation (n=5) or allo-PBSCT (n=1) from unrelated HLA matched donors. All patients received myeloablative ...
Natural Killer (NK) cells are lymphocytes of innate immunity that respond to virus infected and tumor cells. After allogeneic transplantation, NK cells are the first reconstituting lymphocytes, but are dysfunctional. Manipulating this first wave of lymphocytes could be instrumental in reducing the 40% relapse rate following transplantation with reduced intensity conditioning. NK cells express numerous activating and inhibitory receptors. Some recognize classical or non-classical HLA class I ligands, others recognize class I-like ligands or unrelated ligands. Dominant in the NK cell transplant literature are killer cell immunoglobulin-like receptors (KIR), encoded on chromosome 19q. Inhibitory KIR recognition of cognate HLA class I ligand is responsible for NK cell education, which makes them tolerant of healthy cells, but responsive to unhealthy cells having reduced expression of HLA class I. KIR A and KIR B are functionally distinctive KIR haplotype groups that differ in KIR gene content. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
TY - JOUR. T1 - The Complex Needs of Pediatric Hematopoietic Stem Cell Donors and Their Families. T2 - Challenges and Opportunities. AU - Derrington, Sabrina F.. AU - Essner, Bonnie S.. PY - 2016/11/1. Y1 - 2016/11/1. KW - health-related quality of life. KW - palliative care. KW - resilience. KW - siblings. UR - http://www.scopus.com/inward/record.url?scp=84994479686&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84994479686&partnerID=8YFLogxK. U2 - 10.1016/j.jpeds.2016.08.052. DO - 10.1016/j.jpeds.2016.08.052. M3 - Editorial. VL - 178. SP - 14. EP - 15. JO - Journal of Pediatrics. JF - Journal of Pediatrics. SN - 0022-3476. ER - ...
The global Hematopoietic Stem Cells Transplantation (HSCT) Market is one amongst the enormously classified markets. The global Hematopoietic Stem Cells Transplantation (HSCT) market report offers information related to import and export, along with the current business chain in the market at the global level. It also delivers a plan regarding the expansion of supply and demand of the generated products and offering services compared with the key market players Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems of the Hematopoietic Stem Cells Transplantation (HSCT) market globally.. Apply here for the sample copy of the report @: https://www.reportsbuzz.com/request-for-sample.html?repid=71502. A deep investigation of the Hematopoietic Stem Cells Transplantation (HSCT) market depends on global patterns, which have been recently incorporated into the study, is also included in the report. Furthermore, The report presents a detailed segmentation ...
The latest market report published by Credence Research, Inc. Global Hematopoietic Stem Cells Transplantation Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022, the hematopoietic stem cells transplantation market was valued at USD 3,741.3 Mn in 2015, and is expected to reach USD 7,796.1 Mn by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.. Market Insights. Over 50 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further ...
Posaconazole (PCZ) is the latest triazole antifungal agent that has been approved for prophylaxis of invasive aspergillosis in high-risk immunocompromised patients, such as allogeneic hematopoietic stem cell transplantation patients, who develop graft-versus-host disease (GVHD). PCZ has high interindividual variability with regard to its plasma trough concentrations (C(min)). Moreover the concentration-efficiency relationship remains to be better characterized in prophylaxis. To determine the variability factors in plasma concentrations, PCZ C(min) and clinical parameters (localization of GVHD, presence of diarrhea, and diagnosis of invasive aspergillosis) were collected retrospectively in 29 consecutive allogeneic hematopoietic stem cell transplantation patients who developed GVHD and were receiving prophylactic PCZ (200 mg 3 times/day ≥ 7 days). Blood samples were analyzed at steady state to determine PCZ C(min) by liquid chromatography-tandem mass spectrometry. The average PCZ C(min) value ...
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of fludarabine to a conditioning regimen with myeloablative doses of Busulfan and reduced dosages of Cytoxan prior to HSCT will overcome the engraftment barrier posed ...
Extramedullary relapse of AML following allogeneic HSCT remains a poorly understood post-HSCT outcome. The incidence of extramedullary relapse in this study (10%) is consistent with previously reported rates over the past 35 years despite many changes in allogeneic HSCT practices.21,22 Although it is possible that patients with risk factors for extramedullary relapse are currently more likely to undergo allogeneic HSCT than they were in the past, it is more likely that the stable incidence reflects a lack of progress in this scenario. In this series of patients, we confirmed that the increased risk of extramedullary relapse for most previously reported risk factors, including pre-HSCT extramedullary disease, FAB M4/M5 AML, and advanced disease status, also apply to the post-HSCT setting.10,20 We did not, however, find there was an increased risk associated with CD56 or T-cell marker expression. While not surprising, our finding that patients with advanced disease status or high risk cytogenetics ...
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease is a life-threatening complication following hematopoietic stem cell transplantation. A quantitative polymerase chain reaction to evaluate EBV-genome copy numbers based on a nested polymerase chain reaction and an end-point dilution was used. Applying this assay EBV load was prospectively screened weekly in 123 patients after transplantation. The results demonstrate that EBV reactivations with more than 1,000 EBV-genome copies measured in 10(5) peripheral blood mononuclear cells were observed in 31 patients (25.2%). Three patients developed lymphoproliferative disease with extremely high EBV-genome copies in peripheral blood mononuclear cells (,100,000 copies/10(5) cells) and plasma. After combined antiviral and immune therapy two of three patients showed a dramatic decrease of EBV load and survived, while the third patient died of lymphoma. A subclinical EBV reactivation was observed in 24 cases (19.5%) with ...
BACKGROUND: Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients over 45 years old. DESIGN AND METHODS: We evaluated, after intensive anti-leukemic remission-induction chemotherapy, the impact of the availability of an HLA-identical sibling donor on an intention-to treat basis. Additionally, all patients without a sibling donor in complete remission after the first consolidation course were randomized to either autologous peripheral blood stem cell transplantation or a second consolidation course consisting of high-dose cytarabine. RESULTS:
Fanconi anemia is a rare and heterogeneous inherited disorder. The natural history of FA is characterized by marrow failure and a risk for clonal evolution. Evolution to acute myeloid leukemia is the main cause of premature mortality. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is considered the treatment of choice in this situation but the evolution is usually poor post-HSCT (due to treatment-related mortality). From August 2006 to December 2011, 6 consecutive patients with FA who received a sequential treatment with chemotherapy and reduced-intensity conditioning for clonal evolution in four different French institutions were reviewed. Five patients presented an AML and one a myelodysplastic syndrome. The sequential strategy consisted of a pre-transplant chemotherapy by fludarabine 30 mg/m2/d 5 days and cytarabine 1gr/m2x2/d 5 days with granulocyte-colony stimulating factor injections (FLAG) followed early after by a reduced-intensity conditioning [4 days cyclophosphamide 10 ...
We recently reported that adult acute myeloid leukemia (AML) patients with granulocytic sarcoma (GS) possessed unique clinical features and poor prognosis. However, the optimal therapeutic strategy for this entity has not been established. Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. We retrospectively analyzed 503 consecutive adult AML patients (median age, 44 years; range, 15-73 years) who received allo-HSCT. A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS (5-year overall survival (OS), 47% vs 44%, respectively, P=0.621). In patients with GS, excellent outcomes were seen in those that underwent allo-HSCT while in complete remission, whereas nine out of ten patients with GS at the time of transplant experienced a relapse within 6 months after allo-HSCT. Local irradiation for GS prior to allo-HSCT and acute and
TY - JOUR. T1 - Vitamin D level after allogeneic hematopoietic stem cell transplant. AU - Sproat, Lisa. AU - Bolwell, Brian. AU - Rybicki, Lisa. AU - Dean, Robert. AU - Sobecks, Ronald. AU - Pohlman, Brad. AU - Andresen, Steven. AU - Sweetenham, John. AU - Copelan, Edward. AU - Kalaycio, Matt. PY - 2011/7. Y1 - 2011/7. N2 - Vitamin D (VD) deficiency can cause osteomalacia, bone pain, muscle weakness, fatigue, and increased risk of fracture, and may precipitate or exacerbate osteopenia and osteoporosis. Patients receiving treatment for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) may have limited exposure to sunlight and often experience gastrointestinal side effects that may decrease their ability to maintain an adequate VD level. We hypothesized that patients with AML and ALL would have a low VD level after allogeneic hematopoietic cell transplant (HCT), and that these patients would have a high incidence of osteoporosis/osteopenia. We therefore studied the incidence of ...
The purpose of this study is to evaluate the outcome of imatinib combined with reduced-intensity allogeneic hematopoietic stem cell transplantation versus
Respiratory virus infections (RVI) have become an increasingly appreciated problem in the hematopoietic stem cell transplant (HSCT) population. A retrospective analysis of 274 patients undergoing 281 HSCT at St. Jude Childrens Research Hospital from January 1994 through December 1997 was performed. Medical and clinical laboratory records were reviewed beginning at the onset of conditioning through the year following each HSCT, and the analysis was done for the first RVI only. Thirty-two (11%) of 281 HSCT cases developed a RVI during the first year post-HSCT. The most frequent cause of RVI was human parainfluenza virus type 3. Univariate analysis was performed to determine the association between risk factors and the cumulative incidence of RVI. Respiratory viruses are frequent causes of infections in the first year post-HSCT in the pediatric population. Only allogeneic transplant and the degree of acute or chronic graft versus host disease were found to be statistically significant risk factors ...
TY - JOUR. T1 - Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome. AU - Goto, Hiroaki. AU - Kaneko, Takashi. AU - Shioda, Yoko. AU - Kajiwara, Michiko. AU - Sakashita, Kazuo. AU - Kitoh, Toshiyuki. AU - Hayakawa, Akira. AU - Miki, Mizuka. AU - Kato, Keisuke. AU - Ogawa, Atsushi. AU - Hashii, Yoshiko. AU - Inukai, Takeshi. AU - Kato, Chiaki. AU - Sakamaki, Hisashi. AU - Yabe, Hiromasa. AU - Suzuki, Ritsuro. AU - Kato, Koji. PY - 2015/1/1. Y1 - 2015/1/1. N2 - Background: Hematopoietic stem cell transplantation (HSCT) is one curable option for high-risk acute lymphoblastic leukemia (ALL); however, transplant-related toxicities might be severe in patients with Down syndrome and ALL (DS-ALL). Procedure: HSCTs performed in patients with DS-ALL were identified in the Japan Society for Hematopoietic Cell Transplantation registry. Results: In the registry data, 11 patients with DS-ALL were identified. The median age at HSCT was 9 years (range: 6-22 ...
TY - JOUR. T1 - Complications and risks in hematopoietic stem cell transplant patients.. AU - Smith, L. A.. AU - Wright-Kanuth, M. S.. PY - 2001/3. Y1 - 2001/3. N2 - Hematopoietic stem cell transplantation is a recognized treatment for hematological diseases such as leukemia and lymphoma, certain solid organ tumors, and a limited number of immunologic disorders. The major risks associated with this procedure are infections and development of graft-vs-host disease. Bacterial or viral agents are the most common cause of infections, but fungal and protozoan organisms may also be isolated. Bacterial infections occur most frequently in the first 30 days after transplant, whereas the onset of viral infections usually occurs later during the first three months posttransplant. Studies have demonstrated that there are a variety of predisposing factors that influence the type of infection a patient develops. These include underlying disease, type of chemotherapy regimen, type of antimicrobial and ...
Ringden, O.; Labopin, M.; Schmid, C.; Sadeghi, B.; Polge, E.; Tischer, J.; Ganser, A.; Michallet, M.; Kanz, L.; Schwerdtfeger, R.; Nagler, A.; Mohty, M. (2016): Sequential chemotherapy followed by reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukemia (AML): a survey from the Acute Leukemia Working Party of EBMT. In: Bone Marrow Transplantation, Vol. 51: S476-S477 ...
Autologous Hematopoietic Stem Cell Transplantation in 48 Patients With End-Stage Chronic Liver Diseases The only presently viable treatment for end-st...
Bone marrow transplantation, 2016; doi:10.1038/bmt.2016.123. Authors: Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G, Budde L E, Pagel J M, Frayo S L, Roden J E, Hedin L, Press O W, Gopal A K et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; City of Hope National Medical Center, Duarte, CA, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; ...
TY - JOUR. T1 - Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation. T2 - Extended follow-up of the multicohort single-arm phase II checkmate 205 trial. AU - Armand, Philippe. AU - Engert, Andreas. AU - Younes, Anas. AU - Fanale, Michelle. AU - Santoro, Armando. AU - Zinzani, Pier Luigi. AU - Timmerman, John M.. AU - Collins, Graham P.. AU - Ramchandren, Radhakrishnan. AU - Cohen, Jonathon B.. AU - De Boer, Jan Paul. AU - Kuruvilla, John. AU - Savage, Kerry J.. AU - Trneny, Marek. AU - Shipp, Margaret A.. AU - Kato, Kazunobu. AU - Sumbul, Anne. AU - Farsaci, Benedetto. AU - Ansell, Stephen M.. PY - 2018/5/10. Y1 - 2018/5/10. N2 - Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT) ...
Objectives: Autologous haematopoietic stem cell transplantation (HSCT) with CD34+ cell selection has recently been used in the treatment of refractory Crohns disease, showing good safety and promising efficacy. We investigated the safety and efficacy of HSCT with unselected peripheral blood stem cells (PBSCs) in moderate-severe refractory Crohns disease.. Patients: Four patients (three male, one female; age range 26-45 years) with active moderate-severe Crohns disease (median Crohns Disease Activity Index (CDAI) 319, range 272-345), refractory or intolerant to multiple drugs including infliximab, were enrolled.. Interventions: Unselected PBSCs were collected after mobilisation with cyclophosphamide (CTX) 1.5 g/m2 and granulocyte-colony stimulating factor (G-CSF) 10 μg/kg. The conditioning regimen included CTX 50 mg/kg on days −5 to −2 and rabbit anti-thymocyte globulin (ATG) 2.5 mg/kg on days −4 to −2.. Main outcome measures: Primary endpoints were toxicity and clinical remission ...
Hotels near Fred Hutchinson Cancer Research Center, Seattle on TripAdvisor: Find 111,494 traveller reviews, 50,608 candid photos, and prices for 276 hotels near Fred Hutchinson Cancer Research Center in Seattle, WA.
TY - JOUR. T1 - Pulmonary graft-versus-host disease after autologous hematopoietic stem cell transplantation. AU - Choi, Sue In. AU - Lee, Eun Joo. AU - Kang, Dong Oh. AU - Lee, Sang Yeub. AU - In, Kwang Ho. AU - Kim, Han Kyeom. AU - Park, Sanghoon. PY - 2016/11/1. Y1 - 2016/11/1. KW - Autologous graft-versus-host disease. KW - Hematopoietic stem cell transplantation. KW - Lung. UR - http://www.scopus.com/inward/record.url?scp=84994388396&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84994388396&partnerID=8YFLogxK. U2 - 10.3904/kjim.2014.110. DO - 10.3904/kjim.2014.110. M3 - Letter. C2 - 26701227. AN - SCOPUS:84994388396. VL - 31. SP - 1181. EP - 1183. JO - Korean Journal of Internal Medicine. JF - Korean Journal of Internal Medicine. SN - 0494-4712. IS - 6. ER - ...
Leonardo Javier Arcuri published a systematic review comparing patient outcomes when treated with haploidentical vs unrelated donor hematopoietic stem cell transplantation (HSCT)
TY - JOUR. T1 - Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. AU - ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. AU - Yoshimitsu, Makoto. AU - Tanosaki, Ryuji. AU - Kato, Koji. AU - Ishida, Takashi. AU - Choi, Ilseung. AU - Takatsuka, Yoshifusa. AU - Fukuda, Takahiro. AU - Eto, Tetsuya. AU - Hidaka, Michihiro. AU - Uchida, Naoyuki. AU - Miyamoto, Toshihiro. AU - Nakashima, Yasuhiro. AU - Moriuchi, Yukiyoshi. AU - Nagafuji, Koji. AU - Miyazaki, Yasuhiko. AU - Ichinohe, Tatsuo. AU - Takanashi, Minoko. AU - Atsuta, Yoshiko. AU - Utsunomiya, Atae. N1 - Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.. PY - 2017/11/16. Y1 - 2017/11/16. N2 - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other ...
Cytomegalovirus (CMV) infection causes significant morbidity and mortality in the setting of immunodeficiency, including the immune reconstitution phase following allogeneic stem cell transplantation (SCT). We assessed CMV-specific CD4(+) and CD8(+) T-cell responses in 87 HLA-A*0201-positive (A2+) and/or B*0702-positive (B7+) allogeneic stem cell transplant recipients using HLA-peptide tetramer staining and cytokine flow cytometry (CFC) to examine the association of CMV-specific immune reconstitution and CMV antigenemia following SCT. Strong CMV-specific T-cell responses recovered in most subjects (77 of 87, 88%) after SCT. Frequencies of CMV-specific CD8(+) T cells were significantly higher in those subjects who experienced early antigenemia relative to those who did not (2.2% vs 0.33%, P =.0002), as were frequencies of CMV-specific CD4(+) T cells (1.71% vs 0.75%, P =.002). Frequencies of CMV-specific CD8(+) T cells were also higher in subjects experiencing late antigenemia (2.4% vs 0.57%). When we
One of the worlds leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. Fred Appelbaum, M.D., director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, asserts that bone marrow - not circulating, peripheral blood, which is the current norm - should be the source for unrelated donor adult stem cells for most patients who require a transplant. The reason: because there is less incidence of chronic graft-versus-host disease (GVHD), which can be a debilitating side effect of transplantation.
TY - JOUR. T1 - UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease. AU - Gregg, K.. AU - Hakki, Morgan. AU - Kaul, D. R.. PY - 2014. Y1 - 2014. N2 - We present a case of foscarnet (FOS) resistance arising from a UL54 mutation after a short duration of FOS exposure, which has not been previously described in a stem cell transplant recipient, to our knowledge. We discuss the use of FOS to treat other viral infections and the implications this may have for the development of resistance mutations and treatment of cytomegalovirus disease.. AB - We present a case of foscarnet (FOS) resistance arising from a UL54 mutation after a short duration of FOS exposure, which has not been previously described in a stem cell transplant recipient, to our knowledge. We discuss the use of FOS to treat other viral infections and the implications this may have for the development of resistance mutations and treatment of cytomegalovirus disease.. KW - ...
TY - JOUR. T1 - Human herpesvirus-6B infection in pediatric allogenic hematopoietic stem cell transplant patients. T2 - Risk factors and encephalitis. AU - Miura, Hiroki. AU - Kawamura, Yoshiki. AU - Hattori, Fumihiko. AU - Tanaka, Makito. AU - Kudo, Kazuko. AU - Ihira, Masaru. AU - Yatsuya, Hiroshi. AU - Takahashi, Yoshiyuki. AU - Kojima, Seiji. AU - Sakaguchi, Hirotoshi. AU - Yoshida, Nao. AU - Hama, Asahito. AU - Yoshikawa, Tetsushi. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: Human herpesvirus-6B (HHV-6B) infection after allogenic hematopoietic stem cell transplantation (allo-HSCT) is known to be associated with post-transplant limbic encephalitis in adults. Meanwhile, the association between HHV-6B infection and central nervous system complications remains unclear in pediatric allo-HSCT patients. Methods: In this study, HHV-6B infection was monitored for more than 50 days after HSCT using virus isolation and real-time PCR. Clinical information such as patient background and encephalitis ...
Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells - while the immune cells are still inside the body.. In a proof-of-principle study to be published April 17 [2017] in Nature Nanotechnology, the team showed that nanoparticle-programmed immune cells, known as T cells, can rapidly clear or slow the progression of leukemia in a mouse model.. Our technology is the first that we know of to quickly program tumor-recognizing capabilities into T cells without extracting them for laboratory manipulation, said Fred Hutchs Dr. Matthias Stephan, the studys senior author. The reprogrammed cells begin to work within 24 to 48 hours and continue to produce these receptors for weeks. This suggests that our technology has the potential to allow the immune system to quickly mount a strong enough response to destroy cancerous cells before the disease becomes ...
The Avgousti lab at the Fred Hutchinson Cancer Research Center has an opening for a postdoctoral fellow. Our laboratory uses a multidisciplinary approach to investigate the mechanisms by which viruses hijack chromatin. Due to the major advancement in sequencing technologies and the expansion of the field of epigenetics, exploiting viruses to investigate chromatin biology has enormous potential. Our goal is to advance basic understanding of viral manipulation of chromatin and uncover new aspects of chromatin biology.. Much like the cellular genome, viral genomes are compacted in virus particles with small basic molecules to maximize space and be poised for gene expression. Some DNA viruses use cellular histone proteins to compact their genomes whereas others use small basic molecules. Adenoviruses encode their own histone-like protein, called protein VII, that forms a beads on a string assembly with the viral genome. By examining protein VII in host chromatin, we discovered that protein VII ...
Fred Hutchinson Cancer Research Center is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents. It
Market your lab products and lab equipment to the life science professionals at the Fred Hutchinson Cancer Research Center in Seattle, WA in the upcoming BioResearch Product Faire™ Event.
TY - JOUR. T1 - Epidemiology and outcomes of clostridium difficile infections in hematopoietic stem cell transplant recipients. AU - Alonso, Carolyn D.. AU - Treadway, Suzanne B.. AU - Hanna, David B.. AU - Huff, Carol Ann. AU - Neofytos, Dionissios. AU - Carroll, Karen C.. AU - Marr, Kieren A.. PY - 2012/4/15. Y1 - 2012/4/15. N2 - Background. Clostridium difficile is the leading cause of infectious diarrhea among hospitalized patients and is a major concern for patients undergoing hematopoietic stem cell transplantation (HSCT). Risk factors and the natural history of C. difficile infection (CDI) are poorly understood in this population.Methods.We performed a retrospective nested case-control study to describe the epidemiology, timing, and risk factors for CDI among adult patients who received HSCTs at our center from January 2003 through December 2008. Results. The overall 1-year incidence of CDI was 9.2% among HSCTs performed (n=999). The median time to diagnosis of CDI was short among both ...
TY - JOUR. T1 - Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. AU - Elsawy, Mahmoud. AU - Storer, Barry E.. AU - Pulsipher, Michael A.. AU - Maziarz, Richard T.. AU - Bhatia, Smita. AU - Maris, Michael B.. AU - Syrjala, Karen L.. AU - Martin, Paul J.. AU - Maloney, David G.. AU - Sandmaier, Brenda M.. AU - Storb, Rainer. AU - Sorror, Mohamed L.. N1 - Publisher Copyright: © 2015 John Wiley & Sons Ltd. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.. PY - 2015/8/1. Y1 - 2015/8/1. N2 - The haematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed in a single centre as a weighted scoring system to predict risks of non-relapse mortality (NRM) following allogeneic haematopoietic cell transplantation. Information on the performance of the HCT-CI in multi-centre studies is lacking in the literature. To that end, a ...
Prognostic effect of allogeneic hematopoietic stem cell transplantation on first and non-first complete remission in acute myeloid leukemia
We evaluated the impact of busulfan dose intensity in patients undergoing reduced toxicity/intensity conditioning allogeneic transplantation in a multicenter retrospective study of 112 consecutive patients. Seventy-five patients were conditioned with busulfan (0.8 mg/kg/dose IV × 8 doses), fludarabine (30 mg/m2/day, days −7 to −3), and 6 mg/kg of ATG [reduced intensity conditioning (RIC) group], while 37 patients received a more-intense conditioning with busulfan (130 mg/m2/day IV, days −6 to −3), fludarabine (40 mg/m2/day, days −6 to −3) and 6 mg/kg of ATG [reduced toxicity conditioning (RTC) group]. At baseline both groups were matched for median age, unrelated donor allografts, and human leukocyte antigen-mismatched allografts. More patients in RIC group had high-risk disease, and higher median comorbidity index. There were no graft rejections. Median time to neutrophil (17 days vs. 15 days; p = 0.003) and platelet engraftment (16 days vs. 11 days; p , 0.001) was significantly ...
A favourable course of Crohn disease has been observed after allogeneic bone marrow transplantation, and there is now mounting evidence that autologous stem cell may be an effective treatment for severe autoimmune diseases. Here, we present the first long-term endoscopic follow-up of a patient with Crohn disease undergoing autologous stem cell transplantation for haematological disease. A 54-year-old woman developed Crohn disease and was submitted to ileocaecal resection. Four months after surgery, the patient contracted acute myeloid leukaemia. She was initially treated with chemotherapy, and subsequently underwent autologous stem cell transplantation. Following transplantation, the patient has remained in clinical remission regarding both diseases, without anti-inflammatory medication. She has undergone ileo-colonoscopy with normal findings at 1, 2, 3 and 5 years after transplantation. This case suggests that autologous stem cell transplantation can change not only the clinical course, but ...
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.
T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using immunomagnetic negative and positive selection procedures
High-dose chemotherapy and autologous stem cell transplantation involves the administration of high doses of anti-cancer drugs and/or radiation therapy for the purpose of killing cancer cells, followed by the infusion of stem cells to rescue or restore bone marrow blood cell production. It is important to understand that high-dose chemotherapy is the treatment for your cancer and damage to the bone marrow is a side effect. Fortunately, the bone marrow can be rescued or replaced with stem cells. For autologous stem cell transplantation, stem cells are collected from the patient before high-dose chemotherapy is delivered. The stem cells are collected form the bone marrow or peripheral blood, processed, frozen and stored. Since these cells are collected from the patient, they are referred to as autologous stem cells and the term autologous stem cell transplantation refers to either bone marrow or peripheral blood stem cell transplantation.. High-dose chemotherapy and autologous stem cell ...
After autologous hematopoietic cell transplantation (HCT) in the first complete remission (CR1), patients with acute myeloid leukemia (AML) may relapse and undergo allogeneic HCT in the second complete remission (CR2). The aim of this study was to analyze the outcome of allogeneic HCT performed in CR2 comparing patients with prior consolidation by autologous HCT versus patients with chemotherapy consolidation. Included were 2619 adults with allogeneic HCT in CR2 from 2000 to 2017 with (n = 417) or without (n = 2202) prior autologous HCT. Patient groups were not entirely comparable; patients with prior autologous HCT were younger, had less often a favorable cytogenetic profile, had more commonly donors other than matched siblings, and more often received reduced-intensity conditioning. In multivariate analysis, nonrelapse mortality risks in patients with prior autologous HCT were 1.34 (1.07 to 1.67; P =.01) after adjustment for age, cytogenetic risk, transplant year, donor, conditioning ...
Bone marrow transplantation, or allogeneic hematopoietic stem cell transplant (HCT), is the only curative therapy for many patients with leukemia. Certain immune cells, called T cells, contained in the donor HCT graft can cause a graft versus leukemia (GVL) effect which eliminates leukemic cells. Unfortunately, there are also donor T cells in the HCT graft that can cause a condition called graft versus host disease (GVHD). GVHD is a life-threatening immune response that remains the major barrier to the success of transplantation. Dr. ...
Stem Cell Transplantation. Stem cell transplantation, also referred as bone marrow transplantation, is currently being performed in the treatment of leukemia, lymphoma, multiple myeloma, various cancers, poorly functioning bone marrow, hereditary anemia, immunodeficiencies and hereditary metabolic diseases.. Stem cells can be obtained from bone marrow, peripheral blood or cord blood. Although bone marrow has been used historically as a stem cell source in the first transplantations, peripheral blood stem cell transplantation is currently performed in 75% of cases. Stem cell from the cord blood is collected as soon as the baby is born. Collected stem cells are stored in sterile conditions.. Stem cell transplants are defined as autologous or allogeneic transplantation.. Autologous transplantation is the process by which the patients own stem cells are collected and stored frozen, then given back to the patient. The most common uses for autologous stem cell transplantation are solid tumors such as ...
Clinical trial for CD22 Positive | B Acute Lymphoblastic Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Lymphocytic Neoplasm | childhood ALL | Lymphoma , Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplant
Juvenile myelomonocytic leukemia (JMML) a serious form of chronic blood cancer can be treated using Allogeneic hematopoietic stem cell transplantation (HSCT).
As you know, autologous stem cell transplantation remains one of the most effective ways to treat myeloma. Any what we call transplant eligible patient who is fit enough, with not too much comorbidity, should get at some point an autologous stem cell transplantation. That remains true even though we have outstanding new drugs, new proteasome inhibitors, new IMiDs and combinations giving, indeed, excellent results. But still today, and that has been shown with numerous phase III trials comparing an upfront transplant versus a delayed one, every time the upfront transplant, autologous stem cell transplant, was superior and actually the very last trial was performed by the IFM in collaboration with the DFCI, the Americans, this is impress actually and the patients very briefly got VRD, Velcade Revlimid dex, and upfront transplant versus a delayed one at relapse and the option of upfront transplant was largely superior to the delayed one.. Now, even though we are improving myeloma treatment, relapse ...
Objectives: The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for autologous haematopoietic stem cell collection. However, different reimbursement criteria have been applied in different countries to select patients eligible for treatment with plerixafor. The objective of this observational study was to describe the plerixafor prescription modalities in daily practice in Belgium. Methods: This open-label, prospective, observational study was conducted in 11 Belgian centres in 114 patients with lymphoma (Hodgkins and non-Hodgkins lymphoma) or MM who were treated with plerixafor according to the SmPC between April 2011 and October 2012. Patients included in another clinical trial with plerixafor were excluded from the study. Results: The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined as a total yield > 2 x ...
Storb R, Gyurkocza B, Storer BE, Maloney DG, Sorror ML, Mielcarek M, Martin PJ, Sandmaier BM. 2013. Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(5):792-8. Abstract ...
TY - JOUR. T1 - Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. AU - Raymond, Gerald V.. AU - Aubourg, Patrick. AU - Paker, Asif. AU - Escolar, Maria. AU - Fischer, Alain. AU - Blanche, Stephane. AU - Baruchel, André. AU - Dalle, Jean Hugues. AU - Michel, Gérard. AU - Prasad, Vinod. AU - Miller, Weston. AU - Paadre, Susan. AU - Balser, John. AU - Kurtzberg, Joanne. AU - Nascene, David R.. AU - Orchard, Paul J.. AU - Lund, Troy. PY - 2019/3. Y1 - 2019/3. N2 - Cerebral adrenoleukodystrophy (CALD) is a rapidly progressing, often fatal neurodegenerative disease caused by mutations in the ABCD1 gene, resulting in deficiency of ALD protein. Clinical benefit has been reported following allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a large multicenter retrospective chart review to characterize the natural history of CALD, to describe outcomes after HSCT, and to identify predictors of ...
Burroughs LM, ODonnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG et al.. 2008. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(11):1279-87. Abstract ...
... (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... See also: List of conditions treated with hematopoietic stem cell transplantation. Indications[edit]. Indications for stem cell ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ...
Robert J. Soiffer (17 November 2008). Hematopoietic Stem Cell Transplantation. Springer. ISBN 978-1-934115-05-3. Retrieved 23 ... Haematopoietic stem cell transplant remains the only curative treatment for CMML. However, due to the late age of onset and ... as well as abnormal looking cells (dysplasia) in at least one type of blood cell. CMML shows characteristics of a ... In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis. In CMML, there are ...
Loren AW, Porter DL (2006). "Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation". Current ... or buffy coat infusion is a form of adoptive immunotherapy used after hematopoietic stem cell transplantation. Formerly, the ... Thomas' Hematopoietic Cell Transplantation, ed. Blume KG, Forman SJ, Appelbaum FR. Blackwell Publishers, Cambridge, MA: 2004. ... These donated white blood cells contain cells of the immune system that can recognize and destroy cancer cells. The goal of ...
HSCT (Hematopoietic Stem Cell Transplantation) department: Chen Hu, Liangding Hu, etc. Neurosurgery: Duan Lian, Weijian Sun, ...
Hütter G, Ganepola S (2011). "Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells". The Scientific ... CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: Current progress and future prospects Current Stem Cell ... "Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation". New England Journal of Medicine. 360 (7): 692-698 ... Both ex-vivo (manipulation of stem or autologous T cell precursors) and in-vivo delivery platforms are being explored. It is ...
Fertility Issues Following Hematopoietic Stem Cell Transplantation. Expert Rev Hematol. 2013, 6 (4): 375-388. PMID 23991924. ... Fertility Issues Following Hematopoietic Stem Cell Transplantation. Expert Rev Hematol. 2013, 6 (4): 375-388. PMID 23991924. ... Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001, 358 (9278): 271 ...
Hematopoietic stem cell transplantation (HSCT) with high intensity conditioning protocol has been performed in a few cases with ... There is a limited but encouraging therapeutic experience of hematopoietic stem cell transplantation for SPS. ... "Autologous haematopoietic stem cell transplantation for neurological diseases". J Neurol Neurosurg Psychiatry. 89 (2): 147-155 ... "Autologous Stem Cell Transplantation for Stiff Person Syndrome". JAMA Neurology. 71 (10): 1296-9. doi:10.1001/jamaneurol. ...
2004).Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation. J Pediatr, 144:569-573. ... Hematopoietic stem cell transplantation (HSCT) can be a treatment option for some patients, however the risk-benefit profile is ... 1987). "Bone marrow transplantation in the treatment of alpha-mannosidosis". Disease in Childhood. 62 (10): 1044-1049. doi: ... Identification of disease-causing mutations is achieved using DNA from peripheral blood cells, by polymerase chain reaction ( ...
"Hematopoietic stem cell transplantation for X-linked thrombocytopenia with mutations in the WAS gene." Journal of clinical ... Recent research has suggested that hematopoietic stem cell transplantation may be a treatment option for patients with XLT ... If WASp is decreased, absent, or altered, then the hematopoietic cells it is found in will show signaling and cytoskeleton ... Platelets are cell fragments in the blood that aid in clotting. Platelets are produced in the bone marrow. Normal platelet ...
... differential admixture and its potential impact on hematopoietic stem cell transplantation". Bone Marrow Research. 2012: 1-13. ... Cell. 131 (7): 1235-47. doi:10.1016/j.cell.2007.11.037. PMID 18160035. S2CID 9263608. Redon R, Ishikawa S, Fitch KR, Feuk L, ... doi:10.1016/j.cell.2015.07.048. PMC 4556133. PMID 26300125. Cenik C, Cenik ES, Byeon GW, Grubert F, Candille SI, Spacek D, et ... CCR5 gene is absent on the surface of cell due to mutation. Without CCR5 gene on the surface, there is nothing for HIV viruses ...
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. „J Clin Oncol". 28 (23), s ... preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.. „Stem Cells ... stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation ... Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first ...
Allogeneic hematopoietic stem cell transplantation should be considered in fit patients with suitable available donor, as long ... July 2008). "Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC". J ... those whose myeloblasts express T-cell surface markers, CD13, or CD14 those with high peripheral white blood cell counts ... Meningeal leukemia, or invasion of the subarachnoid space by leukemic cells, is usually considered distinct from chloroma, ...
"Dry eye after haematopoietic stem cell transplantation". The British Journal of Ophthalmology. 83 (10): 1125-30. doi:10.1136/ ... Since iron is a major component of bacterial cell walls, removal of iron breaks down the cell wall, which in turn breaks down ... Secretory cells are found in a group, or acinus (plural, acini). Each acinus is located at the terminal part of the gland ... Graft versus host disease after allogeneic bone marrow transplantation may manifest as dry mouth and many small mucoceles.[36] ...
Treatment of the epidermolysis bullosa by transplantation of laminin5 modified stem cells ... "Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources". ... "Long-shot stem-cell treatment gives two brothers a future". Star Tribune. Retrieved 2008-07-22.. ... "Bone Marrow Transplantation. 31 (12): 1704105. doi:10.1038/sj.bmt.1704105.. *^ Fine, Jo-David; Manes, Becky; Frangoul, Haydar ( ...
Prior to haematopoietic stem cell transplantation, radiation or chemotherapy results in damage and activation of host tissues, ... "Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation". Revista da Associação Médica ... "Oral Cancer in Patients After Hematopoietic Stem-Cell Transplantation: Long-Term Follow-Up Suggests an Increased Risk for ... when compared to oral cancer in non-hematopoietic stem cell transplantation patients.[11] ...
For a long time, the most efficient approach had been to use bone marrow graft, or hematopoietic stem cell transplantation. ... Because of all these reasons, bone marrow grafts or hematopoietic stem cell transplantation have seen a decrease in their ... long term follow-up on patients undergone to hematopoietic stem cell transplantation, Minerva Pediatr. 2013 Oct;65(5):487-96. ... The matrix surrounds the cells of the body in an organized meshwork and functions as the glue that holds the cells of the body ...
Virus-specific T-Lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that ... June 2008). "Stem cell transplantation for primary immunodeficiencies". Bone Marrow Transplant. 41 Suppl 2: S83-6. doi:10.1038/ ... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... natural killer cells and monocytes (CD15+), as well as activation markers (HLA-DR, CD25, CD80 (B cells). Tests for T cell ...
"Genetically Modified Hematopoietic Stem Cell Transplantation for HIV-1-infected Patients: Can We Achieve a Cure?". Molecular ... Stem cell based gene therapy[edit]. In the past 7 years, scientists have been using different approaches of stem cell based ... hematopoietic stem cells and progenitor cells (GM-HSPC). Though this study does involve several early stage clinical trials ... Stem cell transplantation[edit]. In 2007, Timothy Ray Brown,[12] a 40-year-old HIV-positive man, also known as "the Berlin ...
... can refer to: Hematopoietic stem cell transplantation, a medical procedure involving transplantation of bone marrow or ... other blood-forming cells High Speed Civil Transport, a NASA project to develop a supersonic passenger aircraft High School ...
Autologous hematopoietic stem cell transplantation (HSCT) is based on the assumption that autoimmune diseases like systemic ... "Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic ... The results of a phase 3 trial, the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, with 156 ... "Autologous Hematopoietic Stem Cell Therapy in Severe Systemic Sclerosis: Ready for Clinical Practice?". JAMA. 311 (24): 2485- ...
Patients after hematopoietic stem cell transplantation (HSCT) are at a higher risk for oral squamous cell carcinoma. Post-HSCT ... December 2010). "Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an ... Squamous-cell carcinoma is a cancer of the squamous cell - a kind of epithelial cell found in both the skin and mucous ... to identify and attack specific cancer cells without harming normal cells." Some targeted therapy used in squamous cell cancers ...
... successfully treated with high-dose ampicillin-sulbactam in a pediatric patient after hematopoietic stem cell transplantation ... AS allows the microbe to bind to target cells and it facilitates the transfer of genetic material between cells.[4] ...
In chemotherapy as a conditioning regimen in hematopoietic stem cell transplantation, a study of patients conditioned with ... "Fertility issues following hematopoietic stem cell transplantation". Expert Review of Hematology. 6 (4): 375-388. PMID 23991924 ... almost all the bone marrow stem cells (cells that produce white and red blood cells) are destroyed, meaning allogenic or ... Chemotherapy drugs are also used in conditioning regimens prior to bone marow transplant (hematopoietic stem cell transplant). ...
... as well as the challenge to find HLA-matched donors for conventional hematopoietic stem cell transplantation, Dr Huisheng Ai, ... Donor's stem cells, which have been processed, will also accelerate functional recovery of recipient's hematopoietic stem cells ... which will be reinitiated by donor's stem cells soon after transplantation, and will play a role as recipient-versus-tumor (RVT ... The cells employed are allogeneic peripheral blood stem cells. Matched HLA between donor and recipient is not necessary. The ...
low levels of antibodies in the blood in people before or after allogeneic haematopoietic stem cell transplantation (a ... Indeed, it is becoming more clear that immunoglobulin can bind to a number of membrane receptors on T cells, B cells, and ... procedure where the patient's bone marrow is cleared of cells and replaced by stem cells from a donor);[15] ... American Journal of Transplantation. 14 (10): 2195-6. doi:10.1111/ajt.12995. PMID 25231064.. ...
See Hematopoietic stem cell transplantation) Of the types of adult stem cells have successfully been isolated and identified, ... Stem cell Embryonic stem cell Induced pluripotent stem cell Induced stem cells Adult stem cell Cell culture Immortalised cell ... Types of adult stem cells include hematopoietic stem cells and mesenchymal stem cells. Hematopoietic stem cells are found in ... A stem cell line is a group of stem cells that is cultured in vitro and can be propagated indefinitely. Stem cell lines are ...
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Stem-cell transplantation was pioneered using bone marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... Journal of Stem Cells. 9 (3): 163-97. PMID 25157450. Park B, Yoo KH, Kim C (December 2015). "Hematopoietic stem cell expansion ...
Gahrton G, Björkstrand B (2000). "Progress in haematopoietic stem cell transplantation for multiple myeloma". J Intern Med 248 ... Wu DC, Boyd AS, Wood KJ (2007). "Embryonic stem cell transplantation: potential applicability in cell replacement therapy and ... "Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics". Exp Cell Res ... Lindvall O (2003). "Stem cells for cell therapy in Parkinson's disease". Pharmacol Res 47 (4): 279-87. PMID 12644384. ...
... activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. ... T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer ... T Cells to protect tumour cells. Nature Communications. March 2018, 9 (1): 948. PMC 5838096. PMID 29507342. doi:10.1038/s41467- ... 细胞毒性T细胞(CTLs, killer T cells)负责杀伤被病毒感染的细胞和癌细胞,在对器官移植
"Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and ... Stopping smoking, respiratory rehabilitation, lung transplantation[2]. Medication. Vaccinations, inhaled bronchodilators and ... "Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell ... "Harnessing the potential of lung stem cells for regenerative medicine". The International Journal of Biochemistry & Cell ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant?. *↑ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... "P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow". Clin Chem ... "Journal of Stem Cells and Regenerative Medicine.. *↑ "Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal ... name="nih",Stem Cell Basics: What are the potential uses of human stem cells and the obstacles that must be overcome before ...
Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proceedings of the ... KK Ballen, F Verter and J Kurtzberg Umbilical cord blood donation: public or private? Bone Marrow Transplantation (2015), 1-8 ... Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells ... Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling ...
Pessach I, Shimoni A, Nagler A (November 2012). "Apoptotic cells in allogeneic hematopoietic stem cell transplantations: " ... Apoptotic cells have been administered simultaneously with hematopoietic stem cells in experimental transplantation models, in ... Side effects of cell transplantationEdit. A study has shown that cell transplantation may cause an increase in body temperature ... Transplantation of stem cells is also known to cause toxicity and graft-versus-host disease (GVHD). ...
It has been found that men with a higher percentage of hematopoietic stem cells in blood lacking the Y chromosome (and perhaps ... Transplantation. 17 (4): 346-354. doi:10.1097/00007890-197404000-00003. ISSN 0041-1337. PMID 4823382. S2CID 35983351.. ... Men with LOY (which was defined as no Y in at least 18% of their hematopoietic cells) have been found to die 5.5 years earlier ... Graves JA (March 2006). "Sex chromosome specialization and degeneration in mammals". Cell. 124 (5): 901-14. doi:10.1016/j.cell. ...
... derived from bone marrow resident hematopoietic stem cells). Developing T cells are referred to as thymocytes and are of ... The newly formed organ resembled a normal thymus histologically and molecularly, and upon transplantation it was able to ... Cells in the thymus can be divided into thymic stromal cells and cells of hematopoietic origin ( ... A rare population of hematopoietic progenitor cells enter the thymus from the blood, and expands by cell division to generate a ...
Chemotherapy, stem cell transplantation, radiation therapy, targeted therapy[1]. Prognosis. Children: 90% five-year survival ... Prior to the development of chemotherapy regimens and hematopoietic stem cell transplant, children were surviving a median ... T cell or pre-B cell Large and heterogeneous (varied) cells ALL - L3 B cell Large and varied cells with vacuoles Mature B-cell ... Chemotherapies or stem cell transplantations may require a platelet transfusion to prevent bleeding.[58][59] Moreover, patients ...
JAK2 mutations are significant because JAK2 plays a role in controlling production of blood cells from hematopoietic stem cells ... The one known curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks.[15] ... which is a reduction in the number of all blood cell types: red blood cells, white blood cells, and platelets. Red blood cells ... In these cases, myelofibrosis occurs as a result of somatic evolution of the abnormal hematopoietic stem cell clone that caused ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant? *↑ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically ... Skin Cells Can Become Embryonic Stem Cells". National Public Radio.. *↑ „Breakthrough Set to Radically Change Stem Cell Debate" ... 2005) "Stem cells: their definition, classification and sources", Stem Cells: From Benchtop to Bedside. World Scientific. ISBN ...
Smith, Franklin O.; Reaman, Gregory H.; Racadio, Judy M. (26 November 2013). Hematopoietic Cell Transplantation in Children ... This registry became a division of the new Tzu Chi Stem Cells Center, which was founded to improve research and treatment ...
Hematopoietic cell transplantation[edit]. On January 13, 2011, City of Hope performed its 10,000th hematopoietic stem cell ... peripheral blood stem cells collected by apheresis, and umbilical cord stem cells.[9] ... contract to facilitate stem cell research from laboratory to clinical study; focus on development and manufacture of stem cell ... The center has performed 13,000 hematopoietic stem cell transplants as of 2016 with patient outcomes that consistently exceed ...
"Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to ... Bone Marrow Transplantation. 24 (12): 1367-8. doi:10.1038/sj.bmt.1702097. PMID 10627651.. ... Elimination of T regulatory cells (CD4+CD25+ T cells) in naive and tumor-bearing hosts ... subsequently actively transported into cancer cells. Once in the cells, the prodrug was enzymatically converted into the active ...
... from adult stem cells or progenitor cells would contribute to overcoming the shortage of donor organs for transplantation. The ... Hematopoietic and immune systems. *Myeloid *Myeloid immune system. *Lymphoid *Lymphoid immune system ... activates beta cells and inhibits alpha cells. *Glycogen/Glucagon: activates alpha cells which activates beta cells and delta ... PP cells (gamma cells or F cells) producing pancreatic polypeptide (,5%). It has been recognized that the cytoarchitecture of ...
... immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation ... Human regulatory T cells rapidly suppress T cell receptor-induced Ca(2+), NF-κB, and NFAT signaling in conventional T cells. „ ... Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming ... IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. „J Exp Med". 210 (6), s. ...
Further information: Hematopoietic stem cell transplantation. For over 30 years, bone marrow has been used to treat people with ... Updated: 16 December 2013 Why Perform a Stem Cell Transplant? *^ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... Stem cells are also in clinical phases for treatment in ophthalmology. Hematopoietic stem cells have been used to treat corneal ... Research using both hematopoietic adult stem cells and embryonic stem cells has provided insight into the possible mechanisms ...
... where they coexist with the recipient's stem cells. The bone marrow stem cells give rise to cells of all hematopoietic lineages ... or heterologous transplant is the transplantation of living cells, tissues or organs from one species to another.[3] Such cells ... The existence of donor stem cells in the recipient's bone marrow causes donor reactive T cells to be considered self and ... T cells. Antigens of phagocytosed graft cells can also be presented by the host's class I MHC molecules to CD8+ T cells.[1][29] ...
The marrow's hematopoietic stem cells-the reservoir of stem cells replenishing exhausted blood cells including white blood ... a b c ABO Incompatible Heart Transplantation in Young Infants. (2009, July 30). ABO Incompatible Heart Transplantation in Young ... Lymphocytes of specific immunity T cells-including the subclasses helper T cells and killer T cells-and B cells. ... As a cell is indicated by the prefix cyto, a cytotoxic influence destroys the cell. Alloreactive killer T cells, also called ...
In some diseases requiring hematopoietic stem cell transplantation, preimplantation genetic diagnosis may be used to give rise ... it can stimulate B-cells that also recognize the same molecule in their B cell receptors. Thus, T cells help B cells make ... These cells have receptors that are similar to B cell receptors, and each cell recognizes only a few class II-peptide ... The immune system uses the HLAs to differentiate self cells and non-self cells. Any cell displaying that person's HLA type ...
"The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation". Bone Marrow Transplantation. ... Peripheral Blood Stem Cells (PBSC):[8] It is possible to collect stem cells from the peripheral blood rather than the bone ... This mobilizes stem cells to travel from the bone marrow into the circulating blood. The stem cells are collected through a ... The Collection Center primarily collects blood stem cells from donors for transplant into a patient. The stem cells are taken ...
Hematopoietic stem cells[edit]. Main article: Hematopoietic stem cell. Hematopoietic stem cells (HSCs) are stem cells that can ... has published a small case series of nine defects in five knees involving surgical transplantation of mesenchymal stem cells ... Stem cell division and differentiation. A - stem cells; B - progenitor cell; C - differentiated cell; 1 - symmetric stem cell ... such as mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, etc.).[72][73] A great deal of adult stem cell ...
Hematopoietic stem cell. Retrieved from "https://en.wikipedia.org/w/index.php?title=Blood_plasma&oldid=868757335" ... Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. "Position ... Blood plasma is a yellowish coloured liquid component of blood that normally holds the blood cells in whole blood in suspension ... this makes plasma the extracellular matrix of blood cells. It makes up about 55% of the body's total blood volume.[1] It is the ...
Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) ... These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those ... A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS ... Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. *H Shimizu. 1. ,12. , ...
Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases. J Leukoc Biol 2002; 72: 609 ... The evolution of hematopoietic stem cell transplantation for multiple sclerosis. Blood 2003; 102: 2314.. *CrossRef , ... Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease. Authors. *. Steven Z. Pavletic. ... Gabor G. Illei, Hematopoietic stem cell transplantation in autoimmune diseases: Is the glass half full or half empty?, ...
A Comparison of Bronchoalveolar Lavage versus Lung Biopsy in Pediatric Recipients after Stem Cell Transplantation, Biology of ... Invasive diagnostic procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant recipients. Authors. * ... Previous article in issue: Avoiding steroids in pediatric renal transplantation: Long-term experience from a single centre ... Previous article in issue: Avoiding steroids in pediatric renal transplantation: Long-term experience from a single centre ...
Full text of Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation : Models in Discovery and Translation 1st ed ... eRESOURCES , Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation : Models in Discovery and Translation ... Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation : Models in Discovery and Translation. ...
Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention ... Outcome of allogeneic hematopoietic stem cell transplantation in children and adults with prior invasive fungal diseases ... Invasive Mold Infections in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation ... Evaluation of Infectious Complications after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant ...
Autologous haematopoietic stem cell transplantation (AHSCT) has been performed as a last treatment resort in a few therapy- ...
... in-depth study and professional analysis on the current state of the Pipeline Drugs for Hematopoietic Stem Cell Transplantation ... The Global Pipeline Drugs for Hematopoietic Stem Cell Transplantation Market 2017 Industry Research Report is a ... 1. Pipeline Drugs for Hematopoietic Stem Cell Transplantation Overview. 2. Global Pipeline Drugs for Hematopoietic Stem Cell ... Hematopoietic Stem Cell Transplantation Market report provides a basic overview of the Pipeline Drugs for Hematopoietic Stem ...
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Stem-cell transplantation was pioneered using bone marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... Journal of Stem Cells. 9 (3): 163-97. PMID 25157450. Park B, Yoo KH, Kim C (December 2015). "Hematopoietic stem cell expansion ...
Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... See also: List of conditions treated with hematopoietic stem cell transplantation. Indications[edit]. Indications for stem cell ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. doi:10.1634/stemcells.19-2- ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ...
This article explores the process of transplantation, how to choose a donor, and the risks involved with such a procedure. Read ... Hematopoietic stem cell transplantation is approved for use in treating some types of cancer and is an experimental treatment ... While the therapy is a form of stem cell transplantation, the stem cells are not the main part of the story. In fact, the key ... Hematopoietic stem cell transplantation was first used as a treatment for some types of cancer but is now widely used as a ...
Purchase Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - 2nd Edition. Print Book & E-Book. ISBN ... Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation 2nd Edition. Models in Discovery and Translation. 0 star ... Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once ... Robert Zeiser serves as Full Professor of Medicine at the Department of Hematology, Oncology and Stem Cell Transplantation ...
H. J. Pegram, D. S. Ritchie, M. J. Smyth et al., "Alloreactive natural killer cells in hematopoietic stem cell transplantation ... "The role of anti-HLA antibodies in hematopoietic stem cell transplantation," Biology of Blood and Marrow Transplantation, vol. ... M. Park, K. N. Koh, B. E. Kim et al., "The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in ... Role of HLA in Hematopoietic Stem Cell Transplantation. Meerim Park1 and Jong Jin Seo2 ...
... To Reflect Significant Incremental Opportunity During 2018-2026 By ... Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent ... expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem ... Important players present in the hematopoietic stem cell transplantation market. Major players operating in the hematopoietic ...
Kumar L, Boya RR, Pai R et al (2016) Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J ... Naithani R, Dayal N, Dixit G (2017) Single versus dual platform analysis for hematopoietic stem cell enumeration using ISHAGE ... Malhotra P, Yanamandra U, Khadwal A et al (2017) Autologous stem cell transplantation for multiple myeloma: single centre ... Prinja S, Kaur G, Malhotra P et al (2017) Cost-effectiveness of autologous stem cell treatment as compared to conventional ...
... changes in the hematopoietic compartment are primarily attributed to cell-intrinsic alterations in hematopoietic stem cells ( ... was sufficient to drive hematopoietic aging phenotypes in young HSCs. We used an ex vivo hematopoietic stem and progenitor cell ... Here, we determined that aging of endothelial cells (ECs), a critical component of the BM microenvironment, ... Infusion of young, HSC-supportive BM ECs enhanced hematopoietic recovery following myelosuppressive injury and restored ...
The journal welcomes submissions related to cell biology, developmental biology, genetics, immunology, pathology, ... pathophysiology of renal disease and progression, clinical nephrology, dialysis, and transplantation. ... B. Bruno, R. A. Zager, M. J. Boeckh et al., "Adenovirus nephritis in hematopoietic stem-cell transplantation," Transplantation ... Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review. Vinod Krishnappa,1 Mohit Gupta,2 Gurusidda Manu,3 ...
... prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated ... but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; ... and administering to the recipient an effective amount of hematopoietic system reconstituting cells. ... The present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor into an ...
... This article is missing citations or needs footnotes.Using inline citations helps guard ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of blood stem cells derived from the bone marrow (that is ... With the availability of the stem cell growth factors GM-CSF and G-CSF, most hematopoietic stem cell transplantation procedures ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ...
This glossary can help you to easily understand medical terms related to the article on Bone Marrow Transplantation ... Transplantation With Human Placental Stem Cells Improves Diabetes Complications in Rats *Stem Cells Help Reverse Diabetes in ... Glossary for Bone Marrow or Hematopoietic Stem Cell Transplantation Do you wish to consult Oncologist for your problem? Ask ... Animation and slides providing graphic explanation of Bone Marrow Transplantation (BMT)/Stem Cell Transplantation that is done ...
Complications of Bone Marrow or Hematopoietic Stem Cell Transplantation Complications of Bone Marrow or Hematopoietic Stem Cell ... Complications of bone marrow transplantation/ hematopoietic stem cell transplantation include:. Complications due to ... Complications of Bone Marrow Transplantation. Complications of Bone Marrow or Hematopoietic stem cell transplantation include ... Luxury Furniture Exhausts Budget of Japan Stem Cell Body. * Transplantation With Human Placental Stem Cells Improves Diabetes ...
Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency.. van Straaten S1,2, ... Hematopoietic Stem Cell Transplantation/adverse effects. *Hematopoietic Stem Cell Transplantation/methods*. *Hematopoietic Stem ... Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency ... Division of Stem Cell Transplantation, University Childrens Hospital, Zurich, Switzerland.. 12. Department of Pediatric ...
Blood stem cell transplantation is accomplished by treating the donor with hematopoietic growth factors, which cause the stem ... Hematopoietic stem cell transplantation: a primer for the primary care physician Message Subject (Your Name) has sent you a ... stem cell transplantation is performed only at specialized centres. Although stem cells can be collected by direct aspiration ... Hematopoietic stem cell transplantation: a primer for the primary care physician. Chantal S. Léger and Thomas J. Nevill ...
Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal ... Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy Brain. 2015 Oct; ... Allogeneic haematopoietic stem cell transplantation should be considered for selected patients with an optimal donor. ... Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal ...
Nutritional status is an important factor influencing outcomes in persons undergoing hematopoietic stem cell transplantation ( ... Prevalence of malnutrition in adult patients previously treated with allogeneic hematopoietic stem-cell transplantation. Clin ... BIA as a prognostic and nutritional status tool for children and adolescents undergoing hematopoietic stem cell transplantation ... and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation. J ...
Successful Hematopoietic Stem Cell Transplantation for Niemann-Pick Disease Type B. Ami J. Shah, Neena Kapoor, Gay M. Crooks, ... Successful Hematopoietic Stem Cell Transplantation for Niemann-Pick Disease Type B. Ami J. Shah, Neena Kapoor, Gay M. Crooks, ... Successful Hematopoietic Stem Cell Transplantation for Niemann-Pick Disease Type B. Ami J. Shah, Neena Kapoor, Gay M. Crooks, ... Successful Hematopoietic Stem Cell Transplantation for Niemann-Pick Disease Type B Message Subject (Your Name) has sent you a ...
Procedure: Stem Cell Transplantation Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:. * ... Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis. The safety and scientific validity of this study ... hematopoietic cells using chemotherapy regimen without total-body irradiation in children undergoing a hematopoietic stem cell ... Drug: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen) Procedure: Stem Cell Transplantation Drug: ...
Allogeneic hematopoietic stem cell transplantation (HSCT) is a standard therapeutic intervention for hematological malignancies ... CRISPR/Cas9-modified hematopoietic stem cells-present and future perspectives for stem cell transplantation. *Alberto Daniel- ... CRISPR/Cas9-modified hematopoietic stem cells-present and future perspectives for stem cell transplantation. Bone Marrow ... Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. ...
Pulmonary complications are common following hematopoietic cell transplantation (HCT) and contribute significantly to its ... Pulmonary complications are common following hematopoietic cell transplantation (HCT) and contribute significantly to its ... The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. Hematol Oncol Stem ... Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Stem Cell Transplantation. Kimberly Fan1, Jennifer McArthur2, R. Ray ...
... clinicaltrials.gov The purpose of this study is to determine if autologous nonmyeloablative hematopoietic stem cell ... Hematopoietic Stem Cell Transplantation. Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals ... Stem Cell Transplantation. The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, ... to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION ...
Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.. Fitzhugh CD1, ... "Hematopoietic Stem Cell Transplantation for Patients with Sickle Cell Disease: Progress and Future Directions" ... "Hematopoietic Stem Cell Transplantation for Patients with Sickle Cell Disease: Progress and Future Directions" ... peripheral blood as the best source for allogeneic hematopoietic stem cell transplantation for patients with sickle cell ...
Yutaro Hino; Noriko Doki; Shuhei Kurosawa; Keita Yamamoto; Masahiro Sakaguchi; Kaito Harada; Shuntaro Ikegawa; Naoki Shingai; Kenichiro Hattori; Yasushi Senoo; Aiko Igarashi; Yuho Najima; Takeshi Kobayashi; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi + Author Information ...
Learn more about Hematopoietic Stem Cell Transplantation at Medical City Dallas DefinitionReasons for ProcedurePossible ... Stem cells produce red blood cells, white blood cells, and platelets. In some cases, stem cells in your bone marrow may not be ... If this happens, you will need new stem cells.. It may take about a month for the donor stem cells in the bone marrow to begin ... www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. Updated August 12, 2013. Accessed ...
Hematopoietic Stem Cell Transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... HSCT involves the intravenous (IV) infusion of autologous or allogeneic stem cells to re-establish hematopoietic function in ... Home » Tag Archives: Hematopoietic Stem Cell Transplantation. Tag Archives: Hematopoietic Stem Cell Transplantation ... Sarah McInerney (40) has obtained chemotherapy and a stem cell transplant, which is not available in Ireland to treat ...
Both donor and patient genetic background might influence the success of bone marrow transplantation and could at least ... Hematopoietic stem cell transplantation (HSCT) is an established therapeutic procedure for several congenital and acquired ... Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children. Raffaella Franca 1,* , Gabriele Stocco ... Keywords: hematopoietic stem cell transplantation; pharmacogenetics; graft vs. host disease; sinusoidal obstructive syndrome ...
  • Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. (nature.com)
  • These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those with GS. (nature.com)
  • However, the optimal therapeutic strategy for GS remains unclear, especially in regards to the indications for need of allogeneic hematopoietic stem cell transplantation (allo-HSCT). (nature.com)
  • This study included all consecutive adult AML aged over 15 years, excluding patients with acute promyelocytic leukemia, who underwent allo-HSCT for the first time between January 2000 and December 2008 at the nine institutions participating in the Kanto Study Group for Cell Therapy. (nature.com)
  • Haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) is associated with an increased risk of graft failure and severe graft-versus-host disease (GVHD). (confex.com)
  • All 35 patients (100%) achieved hematopoietic reconstitution and sustained full donor chimerism within 30 days after HSCT. (confex.com)
  • Pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) often receive intravenous liposomal amphotericin B (L-AmB) as antifungal prophylaxis. (biomedcentral.com)
  • Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk of acquiring severe invasive opportunistic fungal infections. (biomedcentral.com)
  • Allogeneic haematopoietic stem cell transplantation (HSCT) increases the chance of cure compared to only chemotherapy in haematological malignancies, but adds the risk of immunological complications such as graft-versus-host disease (GVHD) and severe infections. (avhandlingar.se)
  • Patients with renal cell carcinoma (RCC, n=10), colon carcinoma (CC, n=6), breast cancer (n=1) or a Klatskin tumour of the liver (n=1) were treated with HSCT with a RIC consisting of Fludarabine and 2 Gray of total body irradiation (TBI). (avhandlingar.se)
  • During the study, four patients died of transplantation-related complications between 45 and 160 days after HSCT and three patients died of tumour progression 92-323 days after HSCT. (avhandlingar.se)
  • Immune recovery analysed by diversity of the T cell receptor (TcR) and the B cell immunoglobulin heavy chain (IgH) using spectratyping of the third complementarity determining region (CDR3) was analysed in 24 patients after RIC (n=13) and myeloablative (n=11) HSCT. (avhandlingar.se)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) offers a potential cure for patients with myelodysplastic syndrome (MDS) who are ineligible for standard-intensity regimens. (kcl.ac.uk)
  • Positive psychological constructs (e.g., optimism and hope) have been associated with superior health outcomes in the recovery from hematopoietic stem cell transplantation (HSCT) in prior work. (edu.au)
  • We used semistructured qualitative interviews in 25 HSCT patients to explore the nature and sources of positive psychological experiences during the first 100 days after transplantation. (edu.au)
  • Participants completed interviews during their HSCT hospitalization and approximately 100 days after transplantation. (edu.au)
  • Acute graft-versus-host-disease (aGvHD) is the major cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). (docphin.com)
  • To explore the outcome of human leukocyte antigen (HLA)-mismatched/haploidentical hematopoietic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia (AL) patients and its related risk factors. (qxmd.com)
  • 4 The study evaluated the tolerability, safety, pharmacokinetics (PK) profile, and efficacy of vedolizumab in 24 patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). (gvhdhub.com)
  • Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is still the only curative treatment for Chronic Myelogenous Leukemia (CML) at present. (ashpublications.org)
  • All of patients received combined transplantation of the G-CSF primed bone marrow and peripheral blood stem cell without T cell depleted, and the prophylaxis regimen for acute GVHD consisted of CSA, short-term MTX, and MMF, but ATG (Fresenius S) and CD25 monoclonal antibody were particularly used in HLA-mismatched HSCT. (ashpublications.org)
  • Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) are often referred for physical therapy (PT) to help improve their quality of life. (elsevier.com)
  • In the past 3 decades, the number of immunocompromised children has increased steadily because of dramatic improvement in survival rates in certain malignancies as a result of intensive curative treatment regimens and an increase in the number of children undergoing life-saving hematopoietic stem cell transplantation (HSCT). (elsevier.com)
  • We launched a multi-center clinical study to examine the safety and feasibility of co-transplantation of MSCs (from third party donors) and haploidentical HSCs into 35 children with severe aplastic anemia (SAA). (confex.com)
  • Peripheral blood stem cell grafts (n = 30) or marrow grafts (n = 2) were infused from human leukocyte antibody (HLA)·matched sibling (n = 30), partially matched related (n = 1), or unrelated (n = 1) donors. (elsevier.com)
  • For only few patients having suitably matched donor, transplantations with stem cells from HLA mismatched related family donors have been increasingly used. (ashpublications.org)
  • Of the 96 patients, 61 suffered from acute myeloid leukemia (AML), and 35 acute lymphoid leukemia (ALL), all of them in non-remission (NR) or relapse before transplantation. (qxmd.com)
  • T cell trafficking to gut-associated lymphoid tissue has been shown to play a key role in acute graft- versus -host disease (aGvHD) establishment in experimental models. (gvhdhub.com)
  • 9 GS was defined as extramedullary tumors that were identified at any time from the diagnosis to transplantation by physical examination and/or imaging studies (computed tomography scan and/or magnetic resonance imaging) and that responded to chemotherapy or irradiation. (nature.com)
  • Here, we report the characteristics and outcomes of six patients with, respectively, clear cell renal carcinoma, diffuse large cell B-cell lymphoma, Hodgkin lymphoma, a microsatellite instable colorectal cancer and melanoma who were treated with PD-1 blocking antibodies. (smw.ch)
  • Falda, M. / Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation . (elsevier.com)
  • Granulocytic sarcoma (GS) is a tumor consisting of malignant granulocytic precursor cells occurring at anatomical sites other than the bone marrow. (nature.com)
  • Gene transfer technologies are promising tools to manipulate donor T cell immunity to enforce the graft-versus-tumor effect, to promote functional immune reconstitution (graft vs. infection), and to prevent or control GvHD. (elsevier.com)
  • In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. (elsevier.com)
  • Nonmyeloablative hematopoietic stem cell transplantation (NST) has been explored in hematological malignancies and solid tumors in an attempt to minimize treatment-related toxicity. (elsevier.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. (elsevier.com)
  • As treatment options are scarce, many clinicians are therefore considering off-label use of ICIs in relapse after allogeneic haematopoietic cell transplantation (HCT) [ 8 - 10 ]. (smw.ch)
  • Sex, age, conditioning regimen (BU/CY or not, dosage of ATG), the number of HLA mismatches between the donor and recipient, and the number of infused mononuclear cells were not independent factors affecting OS, DFS and relapse. (qxmd.com)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • For the journal abbreviated Bone Marrow Transplant , see Bone Marrow Transplantation (journal) . (wikipedia.org)
  • The second edition is fully revised and includes new chapters on microbiome, metabolism, kinase targets, micro-RNA and mRNA regulatory mechanisms, signaling pathways in GVHD, innate lymphoid system development, recovery and function in GVHD, genetically engineered T-cell therapies, immune system engagers for GVHD and graft-versus-tumor, and hematopoietic cell transplant for tolerance induction in solid organ grafts. (elsevier.com)
  • 12 It is the care of the patient after transplantation that can present much more of a challenge to the multidisciplinary care team, especially in the setting of allogeneic transplant. (cmaj.ca)
  • In this article we aim to familiarize primary care practitioners with some of the basics of allogeneic and autologous transplantation, as well as issues relevant to the care of transplant recipients over the short and the long term. (cmaj.ca)
  • 12 12 Stem Cell Transplant and Cellular Therapy Unit, University Hospital, Siena, Italy. (nih.gov)
  • Hematopoietic cell transplant (HCT) is increasingly used as a treatment for various malignant and non-malignant disease processes. (frontiersin.org)
  • If the transplant is successful, new bone marrow cells will produce healthy red blood cells, white blood cells, and platelets. (medicalcityhospital.com)
  • In order for the transplant to be successful, certain markers on the blood cells and bone marrow cells must match. (medicalcityhospital.com)
  • Sarah McInerney (40) has obtained chemotherapy and a stem cell transplant, which is not available in Ireland to treat progressive Multiple Sclerosis. (clarechampion.ie)
  • Related transplant donors must be proven not to have Fanconi anemia in order for a transplantation to succeed. (medscape.com)
  • 5 - 7 A correlation between the economic strength of individual countries and transplant rates, i.e. the number of transplants per number of inhabitants, was reported earlier by the European Group for Blood and Marrow Transplantation (EBMT). (haematologica.org)
  • Autologous stem cell transplant is considered investigational and not medically necessary for individuals with ALL. (unicare.com)
  • Clearly, this more diverse view of the genome has significant implications for allogeneic hematopoietic stem cell transplantation, not least in the generation of transplant antigens but also in terms of individual susceptibility to transplant-related toxicities. (bloodjournal.org)
  • Mature donor T-cells present in the transplant facilitate T-cell reconstitution but also induce GVHD, which itself impairs immune reconstitution. (bioportfolio.com)
  • Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant. (springer.com)
  • At the forefront of research to increase access to hematopoietic stem cell transplantation and improve outcomes, the Center has amassed a clinical database containing information on nearly 350,000 transplant recipients. (ascopost.com)
  • How would you characterize the current status of hematopoietic stem cell transplant? (ascopost.com)
  • They also allow us to consider transplantation in other disorders where high transplant-related mortality rates were previously considered prohibitive-for example, in people with severe sickle cell disease or autoimmune disease. (ascopost.com)
  • What are the main barriers to successful hematopoietic stem cell transplant today, and what will it take to overcome them? (ascopost.com)
  • high-risk patients included male subjects, recipients of stem cells from female donors, patients younger than 10 years, those with nonidentical donors, and those who received radiation therapy in the transplant preparative regimen. (medscape.com)
  • In a study from the United States, long-term survivors of pediatric bone marrow transplantation followed in the Bone Marrow Transplant Survivors Study were compared with survivors of childhood cancer treated without bone marrow transplant from the Childhood Cancer Survivor Study. (medscape.com)
  • Transplant outcomes from MUDs have improved over time and, with fully matched donors, outcomes are now comparable to matched sibling transplantation. (psychiatryadvisor.com)
  • The thymus plays a key role post allogeneic hematopoietic stem cell transplantation in the generation of a broad but self-tolerant T cell repertoire, but it is exquisitely sensitive to a range of insults during the transplant period, including conditioning regimens, corticosteroids, infections, and graft-versus-host disease. (jimmunol.org)
  • Such regenerative strategies may ultimately enable the thymus to play as prominent a role after transplant as it once did in early childhood, allowing a more complete restoration of the T cell compartment. (jimmunol.org)
  • However, complete quantitative and qualitative restoration of the T cell compartment may take many years, or in some cases may not fully recover, and is linked to increased infection, relapse, secondary malignancies, and overall mortality in transplant recipients ( 8 ). (jimmunol.org)
  • In the early post-transplant period, there is peripheral expansion of adoptively transferred donor T cells in the graft or recipient T cells that survive conditioning. (jimmunol.org)
  • Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with Myelodysplastic Syndrome (MDS) or acute Myeloid Leukemia (AML): blood and marrow transplant clinical trials network. (springermedizin.at)
  • To mimic major MHC mismatch transplant which results in acute GVHD impacting gut, skin and liver, lean or DIO C57BL/6 mice received 1050 cGy TBI, bone marrow cells, and different doses of purified T cells from BALB/c mice. (jimmunol.org)
  • 1 , 2 Recently, HHV-6 has been recognized as a serious pathogen in immunocompromised patients, 3 and several case studies of HHV-6-associated encephalopathy have been reported in patients who have undergone hematopoietic stem cell or solid-organ transplant. (ajnr.org)
  • NK cells also mediate anti-viral protection, in particular against cytomegalovirus (CMV), an infection that causes significant morbidity and mortality following transplant. (jcancer.org)
  • In this review, we summarize the recent advances related to the mechanisms, functions, and future clinical prospects of NK cells that can impact post-transplant outcomes. (jcancer.org)
  • MR imaging is typically obtained during the work-up of patients who have undergone allogeneic hematopoietic stem-cell transplant who present with unexplained change in mental status, amnesia, or seizures. (ajnr.org)
  • It then moves on to discuss the immunobiology mechanisms that influence graft-versus-host disease (GVHD), graft-versus-leukemia effect, and transplantation success. (elsevier.com)
  • Donor selection To avoid rejection of the transplanted stem cells or severe graft-versus-host disease , the donor should have the same human leukocyte antigens (HLA) as the recipient. (bionity.com)
  • Complications of Bone Marrow or Hematopoietic stem cell transplantation include graft-versus-host disease, graft failure, increased susceptibility to infections and complications due to the chemotherapy and /or radiation used prior to the procedure. (medindia.net)
  • Graft-versus-host disease occurs due to a reaction between the white blood cells of the donor bone marrow and the recipient s cells. (medindia.net)
  • Accurate determination of immune system compatibility is vital to minimise graft failure and lethal attack from donor cells against recipient's normal tissues (graft-versus-host disease or GvHD). (thedailystar.net)
  • MICA incompatibilities have been associated with an increased graft-versus-host disease (GVHD) incidence, and the MICA-129 (met/val) dimorphism has been shown to influence NKG2D signaling in unrelated hematopoietic stem cell transplantation (uHSCT). (bloodjournal.org)
  • In addition to complications seen from exposure to chemotherapy and radiation, patients undergoing allogeneic transplantation can experience unique late effects secondary to graft versus host disease (GVHD) and autoimmunity. (medscape.com)
  • They are also the central mediators of graft-versus-host disease (GVHD), borne out in the reduction of this complication through use of T cell-depleted grafts ( 7 ). (jimmunol.org)
  • An early biomarker algorithm predicts lethal graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation. (springermedizin.at)
  • Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. (springermedizin.at)
  • These data lay the groundwork for the exploration of EC therapies that can serve as adjuvant modalities to enhance HSC engraftment and accelerate hematopoietic recovery in the elderly population following myelosuppressive regimens. (jci.org)
  • 7 The use of blood stem cells is associated with faster recovery of neutrophils and platelets after transplantation (engraftment) than is the case with bone marrow stem cells. (cmaj.ca)
  • This section describes the 4 components of allogeneic transplantation - conditioning, transplantation, engraftment and immunoreconstitution ( Fig. 2 ) - and provides information about the patient's hospital stay and the risks associated with this type of transplantation. (cmaj.ca)
  • However, in contrast to the 100% donor hematopoietic engraftment typical of myeloablative transplantation, such nonmyeloablative transplants typically resulted in a state of mixed hematopoietic chimerism. (wiley.com)
  • The study, which involved 130 patients, also found that adding fludarabine to conditioning caused three-fold enhancement of hematopoietic cell engraftment. (medscape.com)
  • Co-transplantation of MSCs and hematopoietic stem cells (HSCs) promotes successful engraftment and improves hematopoietic recovery. (springer.com)
  • Surprisingly, the rate of early engraftment of donor-derived BM cells in recipients co-transplanted with CXCR4-MSCs was slightly lower than in the absence of MSCs on day 7. (springer.com)
  • 2004). CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. (springer.com)
  • Disadvantages of CB, compared to BM and MPB, include the low, and sometimes limiting, number of cells collected in single donor units which can be less than optimal for engraftment of many adults and higher weight children, and the relatively slower speed to engraftment of neutrophils and platelets. (stembook.org)
  • While limiting numbers of nucleated cells found in single units of CB can be compensated for by transplantation of more than 1 unit of CB, this use of multiple cord blood units may be associated with increased GVHD, and has not meaningfully reduced the time to neutrophil and platelet engraftment. (stembook.org)
  • 90%) engraftment of donor cells and full correction of a sickle-cell anemia model. (nih.gov)
  • To improve stem cell homing and decrease the prolonged neutropenia that is associated with umbilical cord transplants, a number of strategies to accelerate engraftment are being developed. (dana-farber.org)
  • In utero depletion of fetal hematopoietic stem cells improves engraftment after neonatal transplantation in mice. (sigmaaldrich.com)
  • Although in utero hematopoietic cell transplantation is a promising strategy to treat congenital hematopoietic disorders, levels of engraftment have not been therapeutic for diseases in which donor cells have no survival advantage. (sigmaaldrich.com)
  • We used an antibody against the murine c-Kit receptor (ACK2) to deplete fetal host hematopoietic stem cells (HSCs) and increase space within the hematopoietic niche for donor cell engraftment. (sigmaaldrich.com)
  • both myeloid and lymphoid cell chimerism increased because of higher engraftment of HSCs in the bone marrow. (sigmaaldrich.com)
  • To test the strategy of repeated HSC depletion and transplantation, some mice were treated with ACK2 postnatally, but the increase in engraftment was lower than that seen with prenatal treatment. (sigmaaldrich.com)
  • Such strategies could be used to achieve clinically relevant levels of engraftment to treat congenital stem cell disorders. (sigmaaldrich.com)
  • M-CSF treatment during engraftment or after infection efficiently protected from these pathogens as early as 3 days after transplantation and was effective as a single dose. (rupress.org)
  • The goal was to promote engraftment and let the graft versus tumour effect eliminate tumour cells. (smw.ch)
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood cell production. (wikipedia.org)
  • A study by MacMillan et al reported that alternative donor hematopoietic cell transplantation had a high success rate in patients with Fanconi anemia who did not have a history of opportunistic infections or transfusions and who underwent conditioning with single fraction total body irradiation 300 cGy, cyclophosphamide, fludarabine, and antithymocyte globulin. (medscape.com)
  • A study by Wang et al suggested that in patients with Fanconi anemia, the 1-year overall survival rate following unrelated-donor hematopoietic stem cell transplantation is poor in those with clonal or complete copy gains in the q arm of chromosome 3 or with abnormalities in three or more chromosomes. (medscape.com)
  • Here, we determined that aging of endothelial cells (ECs), a critical component of the BM microenvironment, was sufficient to drive hematopoietic aging phenotypes in young HSCs. (jci.org)
  • We used an ex vivo hematopoietic stem and progenitor cell/EC (HSPC/EC) coculture system as well as in vivo EC infusions following myelosuppressive injury in mice to demonstrate that aged ECs impair the repopulating activity of young HSCs and impart a myeloid bias. (jci.org)
  • In this study, the effects of co-transplantation of HSCs and mouse bone marrow (BM)-derived MSCs overexpressing CXCR4 (CXCR4-MSC) on CXCR4-MSC homing capacity and the reconstitution potential in lethally irradiated mice were evaluated. (springer.com)
  • The frequency of c-kit + Sca + Lin − HSCs was higher in recipient BM following co-transplantation of CXCR4-MSCs compared with the EGFP-MSC control and the BMT only groups. (springer.com)
  • Blood or hematopoietic stem cells (HSCs) live within the bone marrow and are responsible for maintaining life-long blood formation. (ca.gov)
  • Low-dose ACK2 treatment effectively depleted HSCs within the bone marrow with minimal toxicity and the antibody was cleared from the serum before the neonatal transplantation. (sigmaaldrich.com)
  • Hematopoiesis from the transplanted hematopoietic stem cells (HSCs) and progenitor cells (HS/PCs) occurs with a significant lag phase, in which the patient shows severe myeloid cytopenia and is vulnerable to severe and potentially lethal infections, for example by the clinically important gram-negative bacterium Pseudomonas aeruginosa or the fungus Aspergillus fumigatus . (rupress.org)
  • The transplantation of blood-forming hematopoietic stem cells (HSCs) can used as a curative stem cell therapy for a range of blood diseases from immunodeficiencies to leukemias. (ca.gov)
  • Multipotent self-renewing haematopoietic stem cells (HSCs) regenerate the adult blood system after transplantation(1), which is a curative therapy for numerous diseases including immunodeficiencies and leukaemias(2). (ca.gov)
  • Technology Insight: hematopoietic stem cell (HSCs) transplantation for systemic rheumatic disease. (sclero.org)
  • Transplantation of HSCs for the treatment of autoimmune diseases aims to fundamentally correct the dysregulated immune system, which could result in sustained clinical remission or potential cure. (sclero.org)
  • A current list of allogeneic transplantation indications and timing for referral can be found in The National Marrow Donor Program's ''Be The Match"' Donor Registry (see references). (psychiatryadvisor.com)
  • other indications include certain congenital and acquired disorders of the haematopoietic system, autoimmune conditions and hereditary diseases. (who.int)
  • This analysis by the Swiss Blood Stem Cell Transplantation Group, based on data from 2008-2011, describes, treatment rates in Switzerland for specific indications and compares this with data from Germany, France, Italy and the Netherlands, corrected for the size of the population. (smw.ch)
  • Furthermore, cryopreserved cord blood has become an accepted stem cell source [5-7] for certain indications. (smw.ch)
  • We are also planning to participate in trials of chimeric antigen receptor-expressing T (CAR-T) cells capable of recognizing CD19-expressing malignancies such as CLL, acute lymphoblastic leukemia (ALL), and diffuse large B cell lymphoma (DLBCL). (dana-farber.org)
  • The Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation is composed of 12 physicians with subspecialty oncology experience in specific hematologic malignancies and palliative care, which provides clinical expertise and research opportunities for leukemias and MDS, lymphomas, myeloma, and bone marrow transplantation related to these conditions. (jefferson.edu)
  • These advances make transplantation a viable treatment for many more patients with hematologic malignancies. (ascopost.com)
  • Malhotra P, Yanamandra U, Khadwal A et al (2017) Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. (springer.com)
  • Kumar R, Kapoor R, Asthana B et al (2017) Single dose preemptive plerixafor for stem cell mobilization for ASCT after lenalidomide based therapy in multiple myeloma: impact in resource limited setting. (springer.com)
  • For umbilical cord transplantation, see TRANS.00016 Umbilical Cord Blood Progenitor Cell Collection, Storage and Transplantation for additional information and criteria. (unicare.com)
  • Caution is clearly required for non HSC/HPC stem/progenitor cell uses of CB, based on insufficient biological and preclinical information for MSC, EPC, and iPSC. (stembook.org)
  • Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 24, no. 6, 2018, pp. 1250-1259. (unboundmedicine.com)
  • In an October 2014 article published in the Biology of Blood and Marrow Transplantation, Jefferson reported "disease-free and overall survival at 2 years are 74% and 77%, respectively, consistent with the findings (of previous work) and supporting the use of this approach in earlier stage patients lacking a matched related donor. (jefferson.edu)
  • Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell's ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. (openpr.com)
  • Figure 3: Selective in vivo elimination of the Tie2p/e-vector-targeted cells inhibited tumor angiogenesis and slowed tumor growth. (nature.com)
  • Thus, means to enhance numbers and/or potency of collected cells and their engrafting capability through ex-vivo and/or in-vivo maneuvers would likely enhance the efficacy and applicability of CB transplantation. (stembook.org)
  • This system permits the selective elimination of dividing TK+ T-cells in vivo. (bioportfolio.com)
  • Alloanergization of donor cells expanded the CD4 + T-regulatory cell frequency within aDLI which increased further in vivo without impeding expansion of virus- and tumor-associated antigen-specific T-cells. (aacrjournals.org)
  • Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation. (ca.gov)
  • Home › About CIRM › Our Publications › Grantee publications › Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation. (ca.gov)
  • However, while these cells are very important clinically, expanding this stem cell population ex vivo has remained challenging. (ca.gov)
  • They will present early clinical studies that demonstrate the safety of administration of ex vivo expanded NK cells after transplantation using feeder cells that express membrane-bound IL-21. (springer.com)
  • Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once again provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. (elsevier.com)
  • Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees. (bioportfolio.com)
  • This information could provide the means to modulate these cells for greater clinical advantage. (stembook.org)
  • There is also the potential, as yet far from proven in a clinical sense for use of mature cells generated from HSC/HPC, and for non-HSC/HPC uses of CB. (stembook.org)
  • The goal of this clinical research study is to learn if giving donor lymphocyte cells and SGI-110 will help control AML and MDS. (bioportfolio.com)
  • Premature red cell death causes clinical symptoms of hemolytic anemia. (haematologica.org)
  • These results encourage potential clinical applications of M-CSF to prevent severe infections after HS/PC transplantation. (rupress.org)
  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. (springermedizin.at)
  • Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome [published online March 12, 2019]. (clinicaladvisor.com)
  • Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S. Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation. (jcancer.org)
  • Conclusions This study confirms that AHSCT in selected patients with severe dcSSc results in sustained improvement of skin thickening and stabilizations of organ function up to 10 years after transplantation, so leading to a global clinical improvement, as showed by the persistent reduction in the ESSG clinical activity score. (bmj.com)
  • Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. (openpr.com)
  • Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017. (openpr.com)
  • Naithani R, Dayal N, Dixit G (2017) Single versus dual platform analysis for hematopoietic stem cell enumeration using ISHAGE protocol. (springer.com)
  • Deerfield Beach, FL -- ( SBWIRE ) -- 01/19/2017 -- The Global Pipeline Drugs for Hematopoietic Stem Cell Transplantation Market 2017 Industry Research Report is a in-depth study and professional analysis on the current state of the Pipeline Drugs for Hematopoietic Stem Cell Transplantation market. (sbwire.com)
  • By delivering a 'suicide' gene, we selectively eliminated the TEM cells and achieved substantial inhibition of angiogenesis and slower tumor growth without systemic toxicity. (nature.com)
  • Hematopoietic stem-cell transplantation in systemic sclerosis: an update. (bioportfolio.com)
  • Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. (springer.com)
  • Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis. (springer.com)
  • Outcomes of allogeneic hematopoietic cell transplantation in patients with biphenotypic acute leukemia. (springer.com)
  • Allogeneic hematopoietic cell transplantation for leukemic transformation preceded by philadelphia chromosome-negative myeloproliferative neoplasms: a nationwide survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. (springer.com)
  • Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement. (springer.com)
  • Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. (springermedizin.at)
  • Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. (springermedizin.at)
  • Though Dr.Taniguchi of Toranomon Hospital, one of the major hospitals in Tokyo, offered preserve of hematopoietic cell of nuclear workers so they can have it transplanted when they have acute leukemia, Japanese government and Tepco turned it down. (infiniteunknown.net)
  • In case they are exposed to too much radiation, they may have their hematopoietic cell damaged and become unable to make blood cells (Acute leukemia). (infiniteunknown.net)
  • Recently, aging has been linked with the development of age-related clonal hematopoiesis (ARCH), defined as the gradual clonal expansion of hematopoietic stem and progenitor cells (HSPC) carrying recurrent disruptive genetic variants in individuals without a diagnosis of hematologic malignancy. (ovid.com)
  • The key observation that led to the emergence of nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) was the discovery of the immune-mediated allogeneic graft-versus-tumor (GVT) effect ( 4 , 5 ). (wiley.com)
  • Home › About CIRM › Our Publications › Grantee publications › Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation. (ca.gov)
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (wikipedia.org)
  • As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players. (openpr.com)
  • However, we recently reported that adult AML patients with GS had unique characteristics at the time of diagnosis, including younger age, higher white blood cell counts and higher frequency of French-British-American M4 and M5 morphology when compared with those without GS. (nature.com)
  • Thomas' work showed that bone marrow cells infused intravenously could repopulate the bone marrow and produce new blood cells . (bionity.com)
  • With the availability of the stem cell growth factors GM-CSF and G-CSF, most hematopoietic stem cell transplantation procedures are now performed using stem cells collected from the peripheral blood, rather than from the bone marrow. (bionity.com)
  • When the graft fails to take up in the donor and produce new blood cells, it results in graft failure. (medindia.net)
  • Czechowicz A and Weissman I. Purified Hematopoietic Stem Cell Transplantation - The Next Generation of Blood and Immune Replacement. (medindia.net)
  • Although stem cells can be collected by direct aspiration from the bone marrow, with the patient under general or spinal anesthetic ( Fig. 1 ), they are now more commonly harvested from the peripheral blood. (cmaj.ca)
  • Blood stem cell transplantation is accomplished by treating the donor with hematopoietic growth factors, which cause the stem cells to proliferate and circulate freely in the peripheral blood. (cmaj.ca)
  • The blood is then collected by venipuncture and subjected to leukapheresis to obtain the cells for transplantation. (cmaj.ca)
  • Alveolar hemorrhage results from damage of the pulmonary microcirculation, loss of integrity in the alveolar-capillary basement membrane, and accumulation of red blood cells in the alveolar space ( 14 ). (frontiersin.org)
  • The cells will be recollected from peripheral blood by apheresis and refrigerated. (bioportfolio.com)
  • Mild regimens are associated with no significant neutropenia (average neutrophil nadirs of ∼1,000/μl) and have minimal requirements for platelet or red blood cell transfusions. (wiley.com)
  • Stem cells produce red blood cells, white blood cells, and platelets. (medicalcityhospital.com)
  • If the stem cells will be from the donor's blood, the doctor will stick a needle in the donor's large vein or veins in the arms. (medicalcityhospital.com)
  • This machine will spin the blood so that the stem cells are concentrated. (medicalcityhospital.com)
  • The donor may also be required to take pills that cause more stem cells from the bone marrow to go into the blood. (medicalcityhospital.com)
  • Recovery of donor-derived peripheral blood leukocytes and platelets was accelerated when CXCR4-MSCs were co-transplanted with BM cells. (springer.com)
  • Alternative sources of haematopoietic stem cells, such as HLA mismatched (haplo-identical) family members and cord blood, may be available. (nice.org.uk)
  • Cord blood was originally frozen and transplanted after defrost as totally unseparated cells, which included all nucleated cells and lysates from non-nucleated erythrocytes, without washing to ensure that all HSC/HPC collected were infused into the recipient (Broxmeyer et al. (stembook.org)
  • Dr Colin Phipps Diong, Parkway Cancer Centre's new consultant specialising in lymphoma and blood cancers, and haematopoietic stem cell transplantation, explains haematopoietic stem cell transplantation. (thedailystar.net)
  • The term haematopoietic stem cell (HSC) refers to cells made in the blood factory or bone marrow that have the potential to grow into almost any type of blood cell. (thedailystar.net)
  • Bone marrow or HSC transplantation is used clinically to cure patient of a range of blood diseases. (ca.gov)
  • Within two months before the transplantation, all participants will have a medical history, physical exam, and blood tests for ovarian function and platelet count. (knowcancer.com)
  • as such, the positioning of cord blood transplantation should also be reconsidered for AML patients. (springer.com)
  • The postpartum maternal blood helper T (CD3+CD4+ T cell) and the CD4+/CD8+ ratio were decreased, and the cytotoxic T (CD3+CD8+ T) cell increased. (biomedsearch.com)
  • 2 The treatment for PKD is mainly supportive, and consists of regular red blood cell transfusions, splenectomy and chelation therapy for iron overload. (haematologica.org)
  • and 47,000 red blood cells (RBC)/mm 3 . (ajnr.org)
  • Aspergillus Thyroiditis after Allogeneic Hematopoietic Stem Cell Transplantation," Case Reports in Hematology , vol. 2015, Article ID 537187, 3 pages, 2015. (hindawi.com)
  • We excluded patients with hepatomegaly, splenomegaly or disseminated infiltration of leukemia cells in the skin and the infiltration in the cerebrospinal fluid that did not associated with tumors of the central nervous system. (nature.com)
  • More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. (dovepress.com)
  • Additional evidence for the role of donor cells in GVT effects came from findings that recurrent leukemia could be successfully treated solely by infusing additional allogeneic lymphocytes ( 6 ). (wiley.com)
  • Both our center and others are currently developing CAR-T cells directed at myeloma and myeloid leukemia antigens, and we plan to use this technology to better harness the anti-tumor effects of T lymphocytes and natural killer cells. (dana-farber.org)
  • The leukemia segment, on the other hand, is projected to lose a little in the years to come due to the advent of new, improved, and cost efficient drugs that may decrease demand for expensive hematopoietic stem cell transplantation. (sbwire.com)
  • Hematopoietic stem cell transplantation was first used as a treatment for some types of cancer but is now widely used as a therapy for various autoimmune diseases. (medicalnewstoday.com)
  • The time to this event is the time from transplantation to relapse/progression, initiation of non-protocol anti-myeloma therapy, or death from any cause. (clinicaltrials.gov)
  • Thus, transplantation of genetically modified bone marrow progenitors may represent a vehicle for the transport of gene therapy to tumors. (nature.com)
  • 1 Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. (sciencemag.org)
  • Although the only therapy that can cure the pancytopenia is stem cell transplantation, androgens, to which approximately 50-75% of patients respond, are used for those in whom transplantation is not an option. (medscape.com)
  • Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: Current impact and future directions. (springer.com)
  • The treatment that immediately precedes infusion of HSC is called conditioning therapy and is given to help kill tumour cells, "wipe out the memory" of the recipient's immune system, and create "space" within the bone marrow for the incoming stem cells to grow. (thedailystar.net)
  • Stem cells are collected (harvested) before conditioning therapy starts and are usually frozen until it is time for use. (thedailystar.net)
  • The bottom line is that transplantation today is a much more effective therapy and a therapy we are able to apply to many more people. (ascopost.com)
  • Furthermore, we may be able to use immune therapy in the autologous setting, perhaps with vaccination strategies or with genetically altered immune cells (ie, chimeric antigen receptors) that target residual cancer. (ascopost.com)
  • Here, as well, we need to evaluate things like maintenance therapy in the minimal residual disease state, and augmentation of antitumor effects using tumor-specific T cells or natural killer cells. (ascopost.com)
  • First successfully performed in 1959, allogeneic hematopoietic stem cell transplantation (allo-HCT) encompassed the earliest forms of stem cell therapy, cancer immunotherapy, and individualized treatment ( 1 ). (jimmunol.org)
  • The results of this study indicate that early administration of eculizumab may be a safe and effective therapy for hemolytic episodes associated with allogeneic peripheral stem cell transplantation in patients with PNH. (thefreelibrary.com)
  • Autologous haematopoietic stem cell transplantation (AHSCT) has been performed as a last treatment resort in a few therapy-refractory cases with CIDP. (bmj.com)
  • I believe this review series will deepen our understanding of transplantation immunology and recent progress in new immunotherapy-based therapy. (springer.com)
  • Autologous hematopoietic stem cell transplantation was performed and retinoic acid therapy was administered in addition to radiotherapy. (scielo.org.ar)
  • Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal encephalomyopathy, a rare fatal autosomal recessive disease due to TYMP mutations that result in thymidine phosphorylase deficiency. (nih.gov)
  • We have developed a strategy of alloreactive T-cell depletion, using T-cells expressing the Herpes simplex thymidine kinase (TK) suicide gene combined with a ganciclovir (GCV) treatment. (bioportfolio.com)
  • Hematopoietic transplantation remains the only curative treatment for patients with MDS and should be used before patients overtly progress to advanced disease. (aamds.org)
  • Prompted by laboratory findings in zebrafish, we have developed a promising program utilizing Prostaglandin E2 (PGE2) treatment of one umbilical cord unit prior to double cord transplantation. (dana-farber.org)
  • A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. (biomedsearch.com)
  • Disease recurrence is the major cause of treatment failure after transplantation. (ascopost.com)
  • M-CSF treatment showed no adverse effect on long-term lineage contribution or stem cell activity and, unlike G-CSF, did not impede recovery of HS/PCs, thrombocyte numbers, or glucose metabolism. (rupress.org)
  • Hematopoietic stem cell transplantation offers a potential treatment option for patients in this group. (aanem.org)
  • Conversely, autologous haematopoietic stem cell transplantation (AHSCT) has demonstrated to be sometimes an effective treatment in patients (pts) with severe (s) diffuse cutaneous (dc) SSc. (bmj.com)
  • AHSCT was performed using positively selected CD34+ cells. (bmj.com)